Top

Simona F Shaitelman, M.D., Ed.M.

Department of Breast Radiation Oncology, Division of Radiation Oncology

About Dr. Shaitelman

Dr. Shaitelman is a Professor in the Department of Radiation Oncology at the University of Texas MD Anderson Cancer Center. She is a board-certified radiation oncologist with expertise in breast cancer treatments. Dr. Shaitelman treats all types of breast cancer and is interested in targeted radiation treatments, the interaction of radiation, breast cancer and the immune system, and lymphedema. Dr. Shaitelman is the Medical Director of the Breast Cancer-Related Lymphedema Screening Initiative, as a part of which, prospective lymphedema surveillance has become a part of the standard evaluation of breast cancer patients at MD Anderson. As a direct result, over 4,000 breast cancer patients at MD Anderson have had volumetric arm measurements and symptom-based lymphedema screening. She is a co-Investigator on an actively accruing NIH funded clinical trial, Post-Radiation Lymphatic and Systemic Immunity Changes in Post-Radiation Lymphedema development, examining the immune etiology of breast cancer-related lymphedema following radiation treatment. Dr. Shaitelman is the Principal Investigator of the Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects (PRECISE) trial, in which targeted radiation is delivered to breast cancers prior to surgery. The primary goal of this research is to understand the biological impacts of radiation in this setting and to determine if radiation may elicit an immunogenic response in these breast cancers.

Primary Appointment

Professor, Department of Breast Radiation Oncology, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Founder & Director, Department of Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Faculty Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Faculty Member, The University of Texas Graduate School of Biomedical Sciences, Houston, TX

Education & Training

Degree-Granting Education

2006	Harvard Medical School, Boston, Massachusetts, US, MD
2005	Harvard Graduate School of Education, Cambridge, Massachusetts, US, EdM in Medical Education and Adult Learning
2000	Consejo Superior de Investigaciones Cientificas, Barcelona, ES, Fulbright Scholar in History of Medicine
1999	Princeton University, Princeton, New Jersey, US, AB in History

Postgraduate Training

2020-2020	Coaching Certification, MD Anderson Leadership Institute Coach RICE, Houston, Texas
2019-2020	LEADing Others Accelerate, The University of Texas MD Anderson Cancer Center, Houston, Texas
2017-2017	Supervision & Management, Faculty Leadership Development, Leadership Training, The University of Texas MD Anderson Cancer Center, Houston, Texas
2015-2015	Clinical Safety and Effectiveness Program, Office of Performance Improvement, The University of Texas MD Anderson Cancer Center, Houston, Texas
2015-2015	Executive Education, Value Measurement for Health Care, Harvard Business School, Boston, Massachusetts
2013-2014	Heart of Leadership Training, The University of Texas MD Anderson Cancer Center, Houston, Texas
2013-2013	Workshop in Clinical Cancer Research, ASCO/AACR Workshop in Methods in Clinical Cancer Research, Vail, Colorado
2009-2011	Clinical Residency, Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan
2007-2008	Clinical Residency, Radiation Oncology, Columbia-New York Presbyterian Hospital, New York, New York
2006-2007	Clinical Internship, Internal Medicine, The Mount Sinai Hospital, New York, New York

Board Certifications

2012	American Board of Radiology

Experience & Service

Academic Appointments

Associate Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2023

Assistant Professor, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2017

Administrative Appointments/Responsibilities

Co-Chair, Department of Radiation Oncology, Particle Therapy Biology Working Group, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - 2022

Founder & Director Biomarker Strategic Initiative, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - Present

MD Anderson Global - Breast Radiation Oncology Liaison - Cooper University, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Camden, NJ, 2013 - 2016

Member, MR Linac Consortium Breast Working Group, Stockholm, 2013 - Present

Other Appointments/Responsibilities

Faculty Mentor, Leading Clinical Research Faculty Learning Series, The University of Texas MD Anderson Cancer Center, 2024 - Present

Institutional Coach, LEADing Others Program - The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - Present

Faculty Senator, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2023

Founder and Lead, Female Faculty Working Group, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2023

Biomarker Reviewer, Protocol in a Day - Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2019 - 2022

Member, Patient Experience Council: Patient/Provider Communication Optimization Initiative, Nellie B. Connally Breast Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2019

Member, Integrative Health Initiative, Nellie B. Connally Breast Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2019

Medical Director, Breast Cancer-Related Lymphedema Initiative, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019

Faculty Associate, Institute of Cancer Care Innovation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2018

Member, Patient Flow Through Project, Nellie B. Connally Breast Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2016

Associate Medical Director, Nellie B. Connally Breast Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2016 - 2019

Co-Lead, Clinical Safety and Effectiveness, Team 9: Lymphedema Screening Expansion, Houston, TX, 2015 - 2016

Faculty Member, Network Host Affiliates Multidisciplinary Planning Conference, MD Anderson Physician's Network, Houston, TX, 2014 - 2016

Consultant, MD Anderson Physicians Network, Houston, Texas, 2014 - 2016

Institutional Committee Activities

Member, ASCO Annual Meeting Scientific Program Committee on the Breast Cancer -Local/Regional/Adjuvant Track, 2025 - 2028

Member, Faculty Search Committee, 2023 - 2024

Member, Faculty Search Committee, 2022 - 2023

Member, Radiation Oncology COVID19 Recovery Research Workstream, 2020 - 2020

Member, Institutional Biospecimen Utilization Committee, 2020 - 2022

Member, Data and Biospecimen Access Committee, 2020 - 2022

Member, Nanobiotix Strategic Alliance Joint Steering Committee, 2019 - Present

Member, Faculty Search Committee, Department of Radiation Oncology, 2018 - 2019

Member, Provider Experience Committee, Department of Radiation Oncology, 2018 - 2018

Member, Cancer Survivorship Research Advisory Working Group, 2015 - 2020

Member, Psychosocial, Behavioral, and Health Services Research Committee, 2014 - 2016

Founder and Chair, Lymphedema Research Meeting, 2013 - 2015

Member, Accelerated Partial Breast Irradiation Working Group, 2012 - 2014

Honors & Awards

2023	Top 1% Nationally - Provider and Team, Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS)
2022	Top Abstract, Lymphedema and Wound Care Scientific Session, American Vein & Lymphatic Society, Venous 2022 Forum
2022	Texas Super Doctor, Super Doctors
2022	Mentor to Anusha Gandhi - Early Career Oncologist Award, 104th Annual ARS Meeting
2022	Perfect Score (100%), Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CGCAHPS)
2021	Top Doctor, Castle Connolly
2020	Quality Caring Award Finalist - Breast MultiTeam, The University of Texas MD Anderson Cancer Center
2020	Texas Rising Star, Super Doctors
2020	Mentor to Bhavana Chapman - Susan Papizan Dolan Fellowship in Breast Oncology - Recognition of Research Excellence, The University of Texas MD Anderson Cancer Center
2020	Mentor to Desmond Garner - Albert Koong Awardee for Postgraduate Excellence, Gilbert Fletcher Society
2019	Mentor to Bhavana Chapman - Conquer Cancer Foundation ASCO Merit Awardee, American Society of Clinical Oncology
2019	James D. Cox Mentorship Award, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center
2017	Top 1% Nationally, Consumer Assessment of Healthcare Providers and Systems Measures
2017	MD Anderson Hearst Clinical Innovator Award, The University of Texas MD Anderson Cancer Center
2017	Shirley Stein Scientific Endowed Research Award, The University of Texas MD Anderson Cancer Center
2014	Recipient, National Institutes of Health Loan Repayment Program, National Cancer Institute
2010	Resident Scholarship, San Antonio Breast Cancer Symposium, American Association for Cancer Research
2010	Resident Travel Grant Award, American Brachytherapy Society
2010	Merit Award, ASCO Genitourinary Symposium, American Society of Clinical Oncology
2002	Paul Dudley White Traveling Fellowship, Harvard Medical School
2002	Latin American Studies Travel Grant, David Rockefeller Center, Harvard University
1999	Fulbright Scholar, U.S. Department of State
1995	National Merit Scholar, National Merit Scholarship Corporation
1995	Valedictorian, Horace Greeley High School, Chappaqua, NY

Professional Memberships

American Board of Radiology

2024 - 2024

American Radium Society

2021 - Present

Radiation Research Society

2018 - Present

Alliance for Clinical Trials in Oncology

2018 - Present

Breast Oncology Local Disease Task Force of the National Cancer Institute Breast Cancer Steering Committee

2017 - Present

Elekta MRL Breast Working Group

2014 - Present

NRG Oncology

2013 - Present

National Lymphedema Network

2012 - 2020

American Society of Clinical Oncology

2011 - Present

American Brachytherapy Society

2008 - Present

American Society of Radiation Oncology

2007 - Present

Selected Publications

Peer-Reviewed Articles

Reddy, JP, Sherry, AD, Fellman, B, Liu, S, Bathala, TK, Haymaker, CL, Cohen, L, Smith, B, Ramirez, DL, Shaitelman, SF, Chun, SG, Medina-Rosales, M, Teshome, M, Brewster, A, Barcenas, CH, Reuben, A, Ghia, AJ, Ludmir, EB, Weed, D, Shah, SJ, Mitchell, MP, Woodward, W, Gomez, D, Tang, C. Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND). International Journal of Radiation Oncology Biology Physics 121(4):885-893, 2025. e-Pub 2025. PMID: 39486645.
Ben Kacem, M, Bright, SJ, Moran, E, Flint, DB, Martinus, DK, Turner, B, Qureshi, I, Kolachina, RV, Manandhar, M, Marinello, P, Shaitelman, SF, Sawakuchi, GO. PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 39730675.
Ohannesian, N, Mallick, MS, He, J, Qiao, Y, Li, N, Shaitelman, SF, Tang, C, Shinn, EH, Hofstetter, WL, Goltsov, A, Hassan, MM, Hunt, KK, Lin, SH, Shih, WC. Plasmonic nano-aperture label-free imaging of single small extracellular vesicles for cancer detection. Communications Medicine 4(1), 2024. e-Pub 2024. PMID: 38796532.
Poli, E, Dong, W, Shaitelman, SF, Tamirisa, N, Shen, Y, Bedrosian, I. Survival outcomes after omission of surgery for ductal carcinoma in situ. npj Breast Cancer 10(1), 2024. e-Pub 2024.
Corrigan, KL, Bankston, ME, Holliday, EB, Shaitelman, SF, Lee, A, Goodman, C, Fuller, C, Chino, F, Thomas, CR, Jagsi, R, Ludmir, EB. Disease Site Specialization in the Academic Radiation Oncology Workforce. International Journal of Radiation Oncology Biology Physics 120(4):936-939, 2024. e-Pub 2024. PMID: 38897359.
Bright, SJ, Manandhar, M, Flint, DB, Kolachina, RV, Kacem, MB, Martinus, DK, Turner, B, Qureshi, I, McFadden, CH, Marinello, P, Shaitelman, SF, Sawakuchi, GO. ATR inhibition radiosensitizes cells through augmented DNA damage and G2 cell cycle arrest abrogation. JCI Insight 9(19), 2024. e-Pub 2024. PMID: 39235982.
Wanis, KN, Kuerer, HM, Sun, SX, Hunt, KK, Glencer, AC, Teshome, M, Lucci, A, Weiser, R, Johnson, HM, Smith, B, Gutierrez, AM, Shaitelman, SF, Arun, BK. Clinical Outcomes for BRCA Pathogenic Variant Carriers with Breast Cancer Undergoing Breast Conservation. JAMA Network Open:e2418486, 2024. e-Pub 2024. PMID: 38916888.
Yoder AK, Xu T, Youssef P, DeSnyder SM, Marqueen K, Isales L, Lin R, Smith BD, Woodward WA, Stauder MC, Strom EA, Aldrich MB, Shaitelman SF. Association between symptom burden and early lymphatic abnormalities after regional nodal irradiation for breast cancer. Pract Radiat Oncol 14(3):e180-e189, 2024. e-Pub 2024. PMID: 37914083.
Shaitelman, SF, Anderson, BM, Arthur, D, Bazan, JG, Bellon, JR, Bradfield, L, Coles, CE, Gerber, NK, Kathpal, M, Kim, L, Laronga, C, Meattini, I, Nichols, EM, Pierce, LJ, Poppe, M, Spears, PA, Vinayak, S, Whelan, T, Lyons, J. Partial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ. Practical radiation oncology 14(2):112-132, 2024. e-Pub 2024. PMID: 37977261.
Guhan M, Crane SM, Valerius LS, Cruz D, Smith BD, Woodward WA, Mitchell MP, Valero V, Rauch GM, Krishnamurthy S, Warnecke CL, Kuerer HM, Shaitelman SF. Patient interest in exploring non-surgical treatment approaches for early stage breast cancer: A qualitative study. Int J Radiat Oncol Biol Phys 118(2):443-454, 2024. e-Pub 2024. PMID: 37802228.
Baroudi H, Huy Minh Nguyen CI, Maroongroge S, Smith BD, Niedzielski JS, Shaitelman SF, Melancon A, Shete S, Whitaker TJ, Mitchell MP, Yvonne Arzu I, Duryea J, Hernandez S, El Basha D, Mumme R, Netherton T, Hoffman K, Court L. Automated contouring and statistical process control for plan quality in a breast clinical trial. Phys Imaging Radiat Oncol 28:100486, 2023. e-Pub 2023. PMID: 37712064.
Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM, Study Group ER. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open 6(9):e2333933, 2023. e-Pub 2023. PMID: 37707811.
Shi JJ, Lei X, Chen YS, Chavez-MacGregor M, Bloom E, Schlembach P, Shaitelman SF, Buchholz TA, Kaiser K, Ku K, Smith BD, Smith GL. Socioeconomic Barriers to Randomized Clinical Trial Retention in Patients Treated With Adjuvant Radiation for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 116(1):122-131, 2023. e-Pub 2023. PMID: 36724858.
Gandhi A, Xu T, DeSnyder SM, Smith GL, Lin R, Barcenas CH, Stauder MC, Hoffman KE, Strom EA, Ferguson S, Smith BD, Woodward WA, Perkins GH, Mitchell MP, Garner D, Goodman CR, Aldrich M, Travis M, Lilly S, Bedrosian I, Shaitelman SF. Prospective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer: The foundation for building a patient-centered screening program. Breast 68:205-215, 2023. e-Pub 2023. PMID: 36863241.
Vang AR, Shaitelman SF, Rasmussen JC, Chan W, Sevick-Muraca EM, Aldrich MB. Plasma Cytokines/Chemokines as Predictive Biomarkers for Lymphedema in Breast Cancer Patients. Cancers (Basel) 15(3), 2023. e-Pub 2023. PMID: 36765631.
Shen Y, Ning J, Lin HY, Shaitelman SF, Kuerer HM, Bedrosian I. Effectiveness Without Efficacy: Cautionary Tale from a Landmark Breast Cancer Randomized Controlled Trial. J Cancer 14(2):193-199, 2023. e-Pub 2023. PMID: 36741254.
Kuerer, HM, Smith, B, Shaitelman, SF, Krishnamurthy, S, Yang, WT, Valero, V, Shen, Y, Lin, Y, Lucci, A, Boughey, JC, White, RL, Diego, EJ, Rauch, GM, Moseley, T, van la Parra, RF, Adrada, BE, Leung, J, Sun, SX, Teshome, M, Miggins, MV, Hunt, KK, DeSnyder, SM, Ehlers II, RA, Hwang, RF, Colen, JS, Arribas, E, Samiian, L, Lesnikoski, BA, Piotrowski, MJ, Bedrosian, I, Chong, CD, Correa Refinetti, AP, Huang, ML, Candelaria, RP, Loveland-Jones, C, Mitchell, MP. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy. The lancet oncology 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
Corrigan KL, Kouzy R, Jaoude JA, Patel RR, Layman RM, Giordano SH, Woodward WA, Smith BD, Shaitelman SF, Ludmir EB. Inclusion of premenopausal women in breast cancer clinical trials. Breast 66:204-207, 2022. e-Pub 2022. PMID: 36327626.
Anderson, BM, Arthur, D, Hannoun-Levi, JM, Kamrava, M, Khan, AJ, Kuske, R, Scanderbeg, DJ, Shah, C, Shaitelman, SF, Showalter, TN, Vicini, FA, Wazer, DE, Yashar, CM. Partial breast irradiation. Brachytherapy 21(6):726-747, 2022. e-Pub 2022. PMID: 36117086.
Farley CR, Irwin S, Adesoye T, Sun SX, DeSnyder SM, Lucci A, Shaitelman SF, Chang EI, Ueno NT, Woodward WA, Teshome M. ASO Visual Abstract: Lymphedema in Inflammatory Breast Cancer Patients Following Trimodal Treatment. Ann Surg Oncol 29(10):6379-6380, 2022. e-Pub 2022. PMID: 36030283.
Farley CR, Irwin S, Adesoye T, Sun SX, DeSnyder SM, Lucci A, Shaitelman SF, Chang EI, Ueno NT, Woodward WA, Teshome M. Lymphedema in Inflammatory Breast Cancer Patients Following Trimodal Treatment. Ann Surg Oncol 29(10):6370-6378, 2022. e-Pub 2022. PMID: 35854031.
Bright SJ, Flint DB, Martinus DKJ, Turner BX, Manandhar M, Kacem MB, McFadden CH, Yap TA, Shaitelman SF, Sawakuchi GO. Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons. Radiat Res 198(4):336-346, 2022. e-Pub 2022. PMID: 35939823.
Aldrich MB, Rasmussen JC, DeSnyder SM, Woodward WA, Chan W, Sevick-Muraca EM, Mittendorf EA, Smith BD, Stauder MC, Strom EA, Perkins GH, Hoffman KE, Mitchell MP, Barcenas CH, Isales LE, Shaitelman SF. Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging. Breast Cancer Res Treat 195(1):33-41, 2022. e-Pub 2022. PMID: 35816269.
Andring LM, Diao K, Sun S, Patel M, Whitman GJ, Schlembach P, Arzu I, Joyner MM, Shaitelman SF, Hoffman K, Stauder MC, Smith BD, Woodward WA. Locoregional Management and Prognostic Factors in Breast Cancer With Ipsilateral Internal Mammary and Axillary Lymph Node Involvement. Int J Radiat Oncol Biol Phys 113(3):552-560, 2022. e-Pub 2022. PMID: 35248602.
Flint DB, Ruff CE, Bright SJ, Yepes P, Wang Q, Manandhar M, Kacem MB, Turner BX, Martinus DKJ, Shaitelman SF, Sawakuchi GO. An empirical model of proton RBE based on the linear correlation between x-ray and proton radiosensitivity. Med Phys 49(9):6221-6236, 2022. e-Pub 2022. PMID: 35831779.
Manandhar M, Bright SJ, Flint DB, Martinus DKJ, Kolachina RV, Kacem MB, Titt U, Martin TJ, Lee CL, Morrison K, Shaitelman SF, Sawakuchi G. Effect of boron compounds on the biological effectiveness of proton therapy. Med Phys 49(9):6098-6109, 2022. e-Pub 2022. PMID: 35754208.
Hanson SE, Lei X, Roubaud MS, DeSnyder SM, Caudle AS, Shaitelman SF, Hoffman KE, Smith GL, Jagsi R, Peterson SK, Smith BD. Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction. JAMA Surg 157(6):e220631, 2022. e-Pub 2022. PMID: 35416926.
Corrigan KL, Lei X, Ahmad N, Arzu I, Bloom E, Chun SG, Goodman C, Hoffman KE, Joyner M, Mayo L, Mitchell M, Nead KT, Perkins GH, Reed V, Reddy JP, Schlembach P, Shaitelman SF, Stauder MC, Strom EA, Tereffe W, Wiederhold L, Woodward WA, Smith BD. Adoption of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Adv Radiat Oncol 7(2):100877, 2022. e-Pub 2022. PMID: 35387420.
Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing. Int J Radiat Oncol Biol Phys 112(2):437-444, 2022. e-Pub 2022. PMID: 34582940.
Chapman BV, Liu D, Shen Y, Olamigoke OO, Lakomy DS, Barrera AMG, Stecklein SR, Sawakuchi GO, Bright SJ, Bedrosian I, Litton JK, Smith BD, Woodward WA, Perkins GH, Hoffman KE, Stauder MC, Strom EA, Arun BK, Shaitelman SF. Outcomes after breast radiotherapy in a diverse patient cohort with a germline BRCA1/2 mutation. Int J Radiat Oncol Biol Phys 112(2):426-436, 2022. e-Pub 2022. PMID: 34610390.
Swanick CW, Jiang J, Maldonado JA, Lei X, Shih YT, Caudle AS, Baumann DP, Giordano SH, Shaitelman SF, Shirvani SM, Smith BD. Differences in Time Burden across Local Therapy Strategies for Early-stage Breast Cancer. Plast Reconstr Surg Glob Open 9(11):e3904, 2021. e-Pub 2021. PMID: 34745797.
Nowakowska MK, Lei X, Thompson MT, Shaitelman SF, Wehner MR, Woodward WA, Giordano SH, Nead KT. Association of statin use with clinical outcomes in patients with triple-negative breast cancer. Cancer 127(22):4142-4150, 2021. e-Pub 2021. PMID: 34342892.
Weng JK, Lei X, Schlembach P, Bloom ES, Shaitelman SF, Arzu IY, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys 111(2):360-370, 2021. e-Pub 2021. PMID: 33992718.
Shah C, Jia X, Hobbs BP, Tendulkar RD, Sittenfeld SMC, Al-Hilli Z, Arthur DW, Keisch ME, Khan AJ, Shaitelman SF, Boyages J, Wazer D, Kundu N, Vicini FA. Outcomes with Partial Breast Irradiation vs. Whole Breast Irradiation: a Meta-Analysis. Ann Surg Oncol 28(9):4985-4994, 2021. e-Pub 2021. PMID: 33393051.
Tamirisa N, Lin H, Shen Y, Shaitelman SF, Karuturi MS, Giordano SH, Babiera GV, Bedrosian I. Impact of adjuvant endocrine therapy in older patients with comorbidities and estrogen receptor-positive, node-negative breast cancer-A National Cancer Database analysis. Cancer 127(13):2196-2203, 2021. e-Pub 2021. PMID: 33735487.
Boyce-Fappiano D, Bedrosian I, Shen Y, Lin H, Gjyshi O, Yoder A, Shaitelman SF, Woodward WA. Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis. NPJ Breast Cancer 7(1):87, 2021. e-Pub 2021. PMID: 34226566.
Flint DB, Bright SJ, McFadden CH, Konishi T, Ohsawa D, Turner B, Lin SH, Grosshans DR, Chiu HS, Sumazin P, Shaitelman SF, Sawakuchi GO. Cell lines of the same anatomic site and histologic type show large variability in intrinsic radiosensitivity and relative biological effectiveness to protons and carbon ions. Med Phys 48(6):3243-3261, 2021. e-Pub 2021. PMID: 33837540.
Gao R, Bai S, Henderson YC, Lin Y, Schalck A, Yan Y, Kumar T, Hu M, Sei E, Davis A, Wang F, Shaitelman SF, Wang JR, Chen K, Moulder S, Lai SY, Navin NE. Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes. Nat Biotechnol 39(5):599-608, 2021. e-Pub 2021. PMID: 33462507.
Paganetti H, Beltran CJ, Both S, Dong L, Flanz JB, Furutani KM, Grassberger C, Grosshans DR, Knopf AC, Langendijk JA, Nyström H, Parodi K, Raaymakers BW, Richter C, Sawakuchi GO, Schippers JM, Shaitelman SF, Teo K, Unkelbach J, Wohlfahrt P, Lomax AJ. Roadmap: proton therapy physics and biology. Phys Med Biol 66(5), 2021. e-Pub 2021. PMID: 33227715.
Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-MacGregor M, Ensor JE, Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V. A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist 26(2):e230-e240, 2021. e-Pub 2021. PMID: 33140515.
Pasalic D, Strom EA, Allen PK, Williamson TD, Poenisch F, Amos RA, Woodward WA, Stauder MC, Shaitelman SF, Smith BD, Perkins GH, Tereffe W, Hoffman KE. Proton Accelerated Partial Breast Irradiation: Clinical Outcomes at a Planned Interim Analysis of a Prospective Phase 2 Trial. Int J Radiat Oncol Biol Phys 109(2):441-448, 2021. e-Pub 2021. PMID: 32946965.
Thaker NG, Boyce-Fappiano D, Ning MS, Pasalic D, Guzman A, Smith G, Holliday EB, Incalcaterra J, Garden AS, Shaitelman SF, Gunn GB, Fuller CD, Blanchard P, Feeley TW, Kaplan RS, Frank SJ. Activity-Based Costing of Intensity-Modulated Proton versus Photon Therapy for Oropharyngeal Cancer. Int J Part Ther 8(1):374-382, 2021. e-Pub 2021. PMID: 34285963.
Coroneos CJ, Woodward WA, Wong FC, Caudle AS, Shaitelman SF, Kuerer HM, Schaverien MV. Anatomy and physiology of the sentinel lymph nodes of the upper extremity: Implications for axillary reverse mapping in breast cancer. J Surg Oncol 123(4):846-853, 2020. e-Pub 2020. PMID: 33333583.
Vasmel JE, Groot Koerkamp ML, Kirby AM, Russell NS, Shaitelman SF, Vesprini D, Anandadas CN, Currey A, Keller BM, Braunstein LZ, Han K, Kotte AN, de Waard SN, Philippens ME, Houweling AC, Verkooijen HM, van den Bongard HD. Consensus on contouring primary breast tumors on MRI in the setting of neoadjuvant partial breast irradiation in trials. Pract Radiat Oncol 10(6):e466-3474, 2020. e-Pub 2020. PMID: 32315784.
Tamirisa N, Lin H, Shen Y, Shaitelman SF, Sri Karuturi M, Giordano SH, Babiera G, Bedrosian I. Association of Chemotherapy With Survival in Elderly Patients With Multiple Comorbidities and Estrogen Receptor-Positive, Node-Positive Breast Cancer. JAMA Oncol 6(10):1548-1554, 2020. e-Pub 2020. PMID: 32672820.
Chapman BV, Lei X, Patil P, Tripathi S, Nicklaus KM, Grossberg AJ, Shaitelman SF, Thompson AM, Hunt KK, Buchholz TA, Merchant F, Markey MK, Smith BD, Reddy JP. Quantitative 3-Dimensional Photographic Assessment of Breast Cosmesis After Whole Breast Irradiation for Early Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. Adv Radiat Oncol 5(5):824-833, 2020. e-Pub 2020. PMID: 33083644.
Shaitelman SF, Jeruss JS, Pusic AL. Oncoplastic Surgery in the Management of Breast Cancer. J Clin Oncol 38(20):2246-2253, 2020. e-Pub 2020. PMID: 32442070.
Corrigan KL, Mainwaring W, Miller AB, Lin TA, Jethanandani A, Espinoza AF, Piotrowski M, Fuller CD, Stauder MC, Shaitelman SF, Perkins GH, Woodward WA, Giordano SH, Smith BD, Ludmir EB. Exclusion of Men from Randomized Phase III Breast Cancer Clinical Trials. Oncologist 25(6):e990-e992, 2020. e-Pub 2020. PMID: 32272505.
Casal RF, Schwalk AJ, Fowlkes N, Aburto RR, Norton W, Dixon KA, Lin S, Shaitelman SF, Chintalapani G, Hill L. Endobronchial ultrasound-guided injection of NBTXR3 radio-enhancing nanoparticles into mediastinal and hilar lymph nodes: a swine model to evaluate feasibility, injection technique, safety, nanoparticle retention and dispersion. J Thorac Dis 12(5):2317-2324, 2020. e-Pub 2020. PMID: 32642136.
Smith BD, Lei X, Diao K, Xu Y, Shen Y, Smith GL, Giordano SH, DeSnyder SM, Hunt KK, Teshome M, Jagsi R, Shaitelman SF, Peterson SK, Swanick CW. Effect of Surgeon Factors on Long-Term Patient-Reported Outcomes After Breast-Conserving Therapy in Older Breast Cancer Survivors. Ann Surg Oncol 27(4):1013-1022, 2020. e-Pub 2020. PMID: 31916092.
Esho TO, Chung CV, Thompson JU, Dehghanpour M, Sutton JR, Shaitelman SF, Kisling KK, Court LE. Optimization of autogenerated chest-wall radiation treatment plans developed for postmastectomy breast cancer patients in underserved clinics. Med Dosim 45(1):102-107, 2020. e-Pub 2020. PMID: 31956001.
Moreno AC, Lin YH, Bedrosian I, Shen Y, Babiera GV, Shaitelman SF. Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes. J Cancer 11(6):1341-1350, 2020. e-Pub 2020. PMID: 32047541.
Bright SJ, Flint DB, Chakraborty S, McFadden CH, Yoon DS, Bronk L, Titt U, Mohan R, Grosshans DR, Sumazin P, Shaitelman SF, Asaithamby A, Sawakuchi GO. Nonhomologous End Joining Is More Important Than Proton Linear Energy Transfer in Dictating Cell Death. Int J Radiat Oncol Biol Phys 105(5):1119-1125, 2019. e-Pub 2019. PMID: 31425731.
Raber BM, Lin H, Shen Y, Shaitelman SF, Bedrosian I. Trends in Regional Nodal Management of Breast Cancer Patients with Low Nodal Burden. Ann Surg Oncol 26(13):4346-4354, 2019. e-Pub 2019. PMID: 31605340.
Buszek SM, Shaitelman SF. In Reply to Braunstein. Int J Radiat Oncol Biol Phys 105(5):1162-1163, 2019. e-Pub 2019. PMID: 31748138.
Kwon S, Janssen CF, Velasquez FC, Zhang S, Aldrich MB, Shaitelman SF, DeSnyder SM, Sevick-Muraca EM. Radiation Dose-Dependent Changes in Lymphatic Remodeling. Int J Radiat Oncol Biol Phys 105(4):852-860, 2019. e-Pub 2019. PMID: 31394167.
Buszek SM, Lin HY, Bedrosian I, Tamirisa N, Babiera GV, Shen Y, Shaitelman SF. Lumpectomy Plus Hormone or Radiation Therapy Alone for Women Aged 70 Years or Older With Hormone Receptor-Positive Early Stage Breast Cancer in the Modern Era: An Analysis of the National Cancer Database. Int J Radiat Oncol Biol Phys 105(4):795-802, 2019. e-Pub 2019. PMID: 31377160.
Kisling K, Zhang L, Shaitelman SF, Anderson D, Thebe T, Yang J, Balter PA, Howell RM, Jhingran A, Schmeler K, Simonds H, du Toit M, Trauernicht C, Burger H, Botha K, Joubert N, Beadle BM, Court L. Automated treatment planning of postmastectomy radiotherapy. Med Phys 46(9):3767-3775, 2019. e-Pub 2019. PMID: 31077593.
DeSnyder SM, Kheirkhah P, Travis ML, Lilly SE, Bedrosian I, Buchholz TA, Schaverien MV, Shaitelman SF. Optimizing Patient Positioning to Reduce Variation in the Measurement of Breast Cancer-Related Lymphedema. Lymphat Res Biol 17(4):440-446, 2019. e-Pub 2019. PMID: 30562149.
Christopherson K, Lei X, Barcenas C, Buchholz TA, Garg N, Hoffman KE, Kuerer HM, Mittendorf E, Perkins G, Shaitelman SF, Smith GL, Stauder M, Strom EA, Tereffe W, Woodward WA, Smith BD. Outcomes of Curative-Intent Treatment for Patients With Breast Cancer Presenting With Sternal or Mediastinal Involvement. Int J Radiat Oncol Biol Phys 104(3):574-581, 2019. e-Pub 2019. PMID: 30851348.
Weiss A, Lin H, Babiera GV, Bedrosian I, Shaitelman SF, Shen Y, Kuerer HM, Mittendorf EA, Caudle AS, Hunt KK, Hwang RF. Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. Breast Cancer Res Treat 176(2):435-444, 2019. e-Pub 2019. PMID: 31025270.
Ning MS, Klopp AH, Jhingran A, Lin LL, Eifel PJ, Vedam S, Lawyer AA, Olivieri ND, Guzman AB, Incalcaterra JR, Mesko SM, Pezzi TA, Boyce-Fappiano DR, Shaitelman SF, Frank SJ, Thaker NG. Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. Brachytherapy 18(4):445-452, 2019. e-Pub 2019. PMID: 30992185.
Coroneos CJ, Wong FC, DeSnyder SM, Shaitelman SF, Schaverien MV. Correlation of L-Dex Bioimpedance Spectroscopy with Limb Volume and Lymphatic Function in Lymphedema. Lymphat Res Biol 17(3):301-307, 2019. e-Pub 2019. PMID: 30388062.
Stecklein SR, Shaitelman SF. In Reply to Mailhot et al. Int J Radiat Oncol Biol Phys 103(5):1281, 2019. e-Pub 2019. PMID: 30900563.
Stecklein SR, Shaitelman SF, Babiera GV, Bedrosian I, Black DM, Ballo MT, Arzu I, Strom EA, Reed VK, Dvorak T, Smith BD, Woodward WA, Hoffman KE, Schlembach PJ, Kirsner SM, Nelson CL, Yang J, Guerra W, Dibaj S, Bloom ES. Prospective Comparison of Toxicity and Cosmetic Outcome After Accelerated Partial Breast Irradiation With Conformal External Beam Radiotherapy or Single-Entry Multilumen Intracavitary Brachytherapy. Pract Radiat Oncol 9(1):e4-e13, 2019. e-Pub 2019. PMID: 30125673.
Grossberg AJ, Lei X, Xu T, Shaitelman SF, Hoffman KE, Bloom ES, Stauder MC, Tereffe W, Schlembach PJ, Woodward WA, Buchholz TA, Smith BD. Association of Transforming Growth Factor β Polymorphism C-509T With Radiation-Induced Fibrosis Among Patients With Early-Stage Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 4(12):1751-1757, 2018. e-Pub 2018. PMID: 30027292.
Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy. Int J Radiat Oncol Biol Phys 102(3):568-577, 2018. e-Pub 2018. PMID: 29928946.
Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, Buchholz D, Chronowski G, Dvorak T, Grade E, Hoffman K, Perkins G, Reed VK, Shah SJ, Stauder MC, Strom EA, Tereffe W, Woodward WA, Amaya DN, Shen Y, Hortobagyi GN, Hunt KK, Buchholz TA, Smith BD. Three-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial. J Clin Oncol 36(35):3495-3503, 2018. e-Pub 2018. PMID: 30379626.
Weiss A, Chu CK, Lin H, Shen Y, Shaitelman SF, Garvey PB, Bedrosian I, Babiera GV. Reconstruction in the Metastatic Breast Cancer Patient: Results from the National Cancer Database. Ann Surg Oncol 25(11):3125-3133, 2018. e-Pub 2018. PMID: 30109538.
Van Wyhe RD, Caudle AS, Shaitelman SF, Perkins GH, Buchholz TA, Hoffman KE, Strom EA, Smith BD, Tereffe W, Woodward WA, Stauder MC. A component of lobular carcinoma in clinically lymph node-negative patients predicts for an increased likelihood of upstaging to pathologic stage III breast cancer. Adv Radiat Oncol 3(3):252-257, 2018. e-Pub 2018. PMID: 30197937.
Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G. Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. Breast Cancer Res Treat 169(3):615-623, 2018. e-Pub 2018. PMID: 29460033.
Netherton T, Li Y, Nitsch P, Shaitelman S, Balter P, Gao S, Klopp A, Muruganandham M, Court L. Interplay effect on a 6-MV flattening-filter-free linear accelerator with high dose rate and fast multi-leaf collimator motion treating breast and lung phantoms. Med Phys 45(6):2369-2376, 2018. e-Pub 2018. PMID: 29611210.
Brunelle CL, Barrio AV, Shaitelman SF, Singhal D, Sayegh HE, Taghian AG. On "Diagnosis of Upper Quadrant Lymphedema Secondary to Cancer: Clinical Practice Guideline from the Oncology Section of the American Physical Therapy Association." Levenhagen K, Davies C, Perdomo M, Ryans K, Gilchrist L. Phys Ther. 2017;97:729-745. Phys Ther 98(4):277-281, 2018. e-Pub 2018. PMID: 29617972.
Ovalle V, Strom EA, Shaitelman S, Hoffman K, Amos R, Perkins G, Tereffe W, Smith BD, Stauder M, Woodward W. Proton Partial Breast Irradiation: Detailed Description of Acute Clinico-Radiologic Effects. Cancers (Basel) 10(4), 2018. e-Pub 2018. PMID: 29642467.
Court LE, Kisling K, McCarroll R, Zhang L, Yang J, Simonds H, du Toit M, Trauernicht C, Burger H, Parkes J, Mejia M, Bojador M, Balter P, Branco D, Steinmann A, Baltz G, Gay S, Anderson B, Cardenas C, Jhingran A, Shaitelman S, Bogler O, Schmeller K, Nelson C, Peterson C, Beadle B Followill D, Howell R. Radiation Planning Assistant - A Streamlined, Fully Automated Radiotherapy Treatment Planning System. J Vis Exp(134), 2018. e-Pub 2018. PMID: 29708544.
Swanick CW, Lei X, Xu Y, Shen Y, Goodwin NA, Smith GL, Giordano SH, Hunt KK, Jagsi R, Shaitelman SF, Peterson SK, Smith BD. Long-term Patient-Reported Outcomes in Older Breast Cancer Survivors: A Population-Based Survey Study. Int J Radiat Oncol Biol Phys 100(4):882-890, 2018. e-Pub 2018. PMID: 29485067.
Shah C, Vicini F, Shaitelman SF, Hepel J, Keisch M, Arthur D, Khan AJ, Kuske R, Patel R, Wazer DE. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy 17(1):154-170, 2018. e-Pub 2018. PMID: 29074088.
Alexander A, Arnold TL, Bishnoi S, Ballinger C, Shaitelman SF, Schaverien MV, Cohen L, Dev M, Ueno NT. Survivorship and Advocacy in Inflammatory Breast Cancer. J Cancer 9(8):1430-1436, 2018. e-Pub 2018. PMID: 29721053.
Ayoub Z, Strom EA, Ovalle V, Perkins GH, Woodward WA, Tereffe W, Smith BD, Shaitelman SF, Stauder MC, Hoffman KE, DeSnyder SM, Garvey PB, Clemens MW, Barcenas CH, Kuerer HM, Kronowitz S. A 10-Year Experience with Mastectomy and Tissue Expander Placement to Facilitate Subsequent Radiation and Reconstruction. Ann Surg Oncol 24(10):2965-2971, 2017. e-Pub 2017. PMID: 28766219.
Moreno AC, Shaitelman SF, Buchholz TA. A clinical perspective on regional nodal irradiation for breast cancer. Breast 34 Suppl 1:S85-S90, 2017. e-Pub 2017. PMID: 28690104.
Moreno AC, Lin YH, Bedrosian I, Shen Y, Stauder MC, Smith BD, Buchholz TA, Babiera GV, Woodward WA, Shaitelman SF. Use of regional nodal irradiation and its association with survival for women with high-risk, early stage breast cancer: A National Cancer Database analysis. Adv Radiat Oncol 2(3):291-300, 2017. e-Pub 2017. PMID: 29114595.
Lin HY, Bedrosian I, Babiera GV, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. Cancer 123(14):2618-2625, 2017. e-Pub 2017. PMID: 28295213.
Shaitelman SF, Howell RM, Smith BD. Effects of Smoking on Late Toxicity From Breast Radiation. J Clin Oncol 35(15):1633-1635, 2017. e-Pub 2017. PMID: 28319432.
Shaitelman SF, Chiang YJ, Griffin KD, De Snyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN. Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat 162(2):217, 2017. e-Pub 2017. PMID: 28185145.
Shaitelman SF, Chiang YJ, Griffin KD, DeSnyder SM, Smith BD, Schaverien MV, Woodward WA, Cormier JN. Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis. Breast Cancer Res Treat 162(2):201-215, 2017. e-Pub 2017. PMID: 28012086.
Reddy JP, Lei X, Huang SC, Nicklaus KM, Fingeret MC, Shaitelman SF, Hunt KK, Buchholz TA, Merchant F, Markey MK, Smith BD. Quantitative Assessment of Breast Cosmetic Outcome After Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys 97(5):894-902, 2017. e-Pub 2017. PMID: 28333010.
Mitchell KB, Lin H, Shen Y, Colfry A, Kuerer H, Shaitelman SF, Babiera GV, Bedrosian I. DCIS and axillary nodal evaluation: compliance with national guidelines. BMC Surg 17(1):12, 2017. e-Pub 2017. PMID: 28173790.
Wilkinson JB, Shah C, Amin M, Nadeau L, Shaitelman SF, Chen PY, Grills IS, Martinez AA, Mitchell CK, Wallace MF, Vicini FA. Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation. Clin Breast Cancer 17(1):55-60, 2017. e-Pub 2017. PMID: 27666436.
Smith BD, Jiang J, Shih YC, Giordano SH, Huo J, Jagsi R, Momoh AO, Caudle AS, Hunt KK, Shaitelman SF, Buchholz TA, Shirvani SM. Cost and complications of local therapies for early stage breast cancer. J Natl Cancer Inst 109(1), 2017. e-Pub 2017. PMID: 27678203.
Shaitelman SF, Stauder MC, Allen P, Reddy S, Lakoski S, Atkinson B, Reddy J, Amaya D, Guerra W, Ueno N, Caudle A, Tereffe W, Woodward WA. Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. J Cancer 8(11):2026-2032, 2017. e-Pub 2017. PMID: 28819403.
Stauder MC, Caudle AS, Allen PK, Shaitelman SF, Smith BD, Hoffman KE, Buchholz TA, Chavez-Macgregor M, Hunt KK, Meric-Bernstam F, Woodward WA. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy. Int J Radiat Oncol Biol Phys 96(3):637-44, 2016. e-Pub 2016. PMID: 27681760.
Swanick CW, Lei X, Shaitelman SF, Schlembach PJ, Bloom ES, Fingeret MC, Strom EA, Tereffe W, Woodward WA, Stauder MC, Dvorak T, Thompson AM, Buchholz TA, Smith BD. Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation. Cancer 122(18):2886-94, 2016. e-Pub 2016. PMID: 27305037.
Thrower SL, Shaitelman SF, Bloom E, Salehpour M, Gifford K. Comparison of Dose Distributions With TG-43 and Collapsed Cone Convolution Algorithms Applied to Accelerated Partial Breast Irradiation Patient Plans. Int J Radiat Oncol Biol Phys 95(5):1520-1526, 2016. e-Pub 2016. PMID: 27315666.
Loveland-Jones C, Lin H, Shen Y, Bedrosian I, Shaitelman S, Kuerer H, Woodward W, Ueno N, Valero V, Babiera G. Disparities in the use of postmastectomy radiation therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys 95(4):1218-25, 2016. e-Pub 2016. PMID: 27209502.
Shirvani SM, Jiang J, Likhacheva A, Hoffman KE, Shaitelman SF, Caudle A, Buchholz TA, Giordano SH, Smith BD. Trends in local therapy utilization and cost for early-stage breast cancer in older women: Implications for payment and policy reform. Int J Radiat Oncol Biol Phys 95(2):605-16, 2016. e-Pub 2016. PMID: 27034179.
Ovalle V, Strom EA, Godby J, Shaitelman SF, Stauder MC, Amos RA, Kuerer HM, Woodward WA, Hoffman KE. Proton partial-breast irradiation for early-stage cancer: Is it really so costly?. Int J Radiat Oncol Biol Phys 95(1):49-51, 2016. e-Pub 2016. PMID: 27084625.
Pan HY, Shaitelman SF, Perkins GH, Schlembach PJ, Woodward WA, Smith BD. Implementing a real-time electronic data capture system to improve clinical documentation in radiation oncology. J Am Coll Radiol 13(4):S1546, 2016. e-Pub 2016. PMID: 26681164.
Caudle AS, Yang WT, Krishnamurthy S, Mittendorf EA, Black DM, Gilcrease MZ, Bedrosian I, Hobbs BP, DeSnyder SM, Hwang RF, Adrada BE, Shaitelman SF, Chavez-MacGregor M, Smith BD, Candelaria RP, Babiera GV, Dogan BE, Santiago L, Hunt KK, Kuerer HM. Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol 34(10):1072-8, 2016. e-Pub 2016. PMID: 26811528.
Huo J, Giordano SH, Smith BD, Shaitelman SF, Smith GL. Contemporary Toxicity Profile of Breast Brachytherapy Versus External Beam Radiation After Lumpectomy for Breast Cancer. Int J Radiat Oncol Biol Phys 94(4):709-718, 2016. e-Pub 2016. PMID: 26972643.
Swisher SK, Vila J, Tucker SL, Bedrosian I, Shaitelman SF, Litton JK, Smith BD, Caudle AS, Kuerer HM, Mittendorf EA. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy. Ann Surg Oncol 23(3):749-56, 2016. e-Pub 2016. PMID: 26511263.
Shaitelman SF, Lin HY, Smith BD, Shen Y, Bedrosian I, Marsh GD, Bloom ES, Vicini FA, Buchholz TA, Babiera GV. Practical implications of the publication of consensus guidelines by the American Society for Radiation Oncology: accelerated partial breast irradiation and the National Cancer Data Base. Int J Radiat Oncol Biol Phys 94(1):338-348, 2016. e-Pub 2016. PMID: 26853342.
Grant SR, Walker GV, Koshy M, Shaitelman SF, Klopp AH, Frank SJ, Pugh TJ, Allen PK, Mahmood U. Impact of insurance status on radiation treatment modality selection among potential candidates for prostate, breast or gynecologic brachytherapy. Int J Radiat Oncol Biol Phys 93(5):968-75, 2015. e-Pub 2015. PMID: 26452570.
Bishop AJ, Ensor J, Moulder SL, Shaitelman SF, Edson MA, Whitman GJ, Bishnoi S, Hoffman KE, Stauder MC, Valero V, Buchholz TA, Ueno NT, Babiera G, Woodward WA. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. Cancer 121(24):4324-32, 2015. e-Pub 2015. PMID: 26348887.
Voss RK, Cromwell KD, Chiang YJ, Armer JM, Ross MI, Lee JE, Gershenwald JE, Stewart BR, Shaitelman SF, Cormier JN. The long-term risk of upper-extremity lymphedema is two-fold higher per lymph node removed in breast cancer patients than in melanoma patients. J Surg Oncol 112(8):834-40, 2015. e-Pub 2015. PMID: 26477877.
Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, Chronowski GM, Dvorak T, Grade E, Hoffman KE, Kelly P, Ludwig M, Perkins GH, Reed V, Shah S, Stauder MC, Strom EA, Tereffe W, Woodward WA, Ensor J, Baumann D, Thompson AM, Amaya D, Davis T, Guerra W, Hamblin L, Hortobagyi G, Hunt KK, Buchholz TA, Smith BD. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol 1(7):931-41, 2015. e-Pub 2015. PMID: 26247543.
Babiera G, Bedrosian I, Shaitelman SF, Kuerer HM, Woodward WA, Ueno NT, Shen Y. Factors influencing treatment of inflammatory breast cancer in the United States. J Clin Oncol 33(28_suppl):118, 2015. e-Pub 2015. PMID: 28147821.
Shah C, Vicini FA, Berry S, Julian TB, Wilkinson JB, Shaitelman SF, Khan A, Finkelstein SE, Goldstein N. Ductal carcinoma in situ of the breast: evaluating the role of radiation therapy in the management and attempts to identify low-risk patients. Am J Clin Oncol 38(5):526-33, 2015. e-Pub 2015. PMID: 25036472.
Shaitelman SF, Tereffe W, Dogan BE, Hess KR, Caudle AS, Valero V, Stauder MC, Krishnamurthy S, Candelaria RP, Strom EA, Woodward WA, Hunt KK, Buchholz TA, Whitman GJ. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. Int J Radiat Oncol Biol Phys 93(1):102-10, 2015. e-Pub 2015. PMID: 26279028.
Lautner M, Lin H, Shen Y, Parker C, Kuerer H, Shaitelman S, Babiera G, Bedrosian I. Disparities in the use of breast-conserving therapy among patients with early-stage breast cancer. JAMA Surg 150(8):778-86, 2015. e-Pub 2015. PMID: 26083835.
Strom EA, Amos RA, Shaitelman SF, Kerr MD, Hoffman KE, Smith BD, Tereffe W, Stauder MC, Perkins GH, Amin MD, Wang X, Poenisch F, Ovalle V, Buchholz TA, Babiera G, Woodward WA. Proton partial breast irradiation in the supine position: Treatment description and reproducibility of a multibeam technique. Pract Radiat Oncol 5(4):e283-90, 2015. e-Pub 2015. PMID: 25804105.
Wobb JL, Chen PY, Shah C, Moran MS, Shaitelman SF, Vicini FA, Mbah AK, Lyden M, Beitsch P. Nomogram for predicting the risk of locoregional recurrence in patients treated with accelerated partial-breast irradiation. Int J Radiat Oncol Biol Phys 91(2):312-318, 2015. e-Pub 2015. PMID: 25446607.
Thaker NG, Hoffman KE, Stauder MC, Shaitelman SF, Strom EA, Tereffe W, Smith BD, Perkins GH, Huo L, Munsell MF, Pusztai L, Buchholz TA, Woodward WA. The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer. Springerplus 4:36, 2015. e-Pub 2015. PMID: 25674496.
Chen PY, Shah C, Moran MS, Shaitelman SF, Vicini FA, Mbah AK, Lyden M, Beitsch PD. Nomogram for predicting the risk of locoregional recurrence in patients treated with accelerated partial-breast irradiation. J Clin Oncol 32(26_suppl):59, 2014. e-Pub 2014. PMID: 28141019.
Lin HY, Shen Y, Li L, Lautner MA, Kuerer HM, Shaitelman SF, Babiera G, Bedrosian I. Effect of hormone receptor status and local treatment on overall survival for early-stage breast cancer. J Clin Oncol 32(26_suppl):60, 2014. e-Pub 2014. PMID: 28141094.
Lin HY, Shen Y, Parker C, Kuerer HM, Shaitelman SF, Babiera G, Bedrosian I. Disparities in utilization of breast-conserving therapy among breast cancer patients. J Clin Oncol 32(26_suppl):104, 2014. e-Pub 2014. PMID: 28141132.
Haynes AB, Bloom ES, Bedrosian I, Kuerer HM, Hwang RF, Munsell MF, Chemaly RF, Graviss LS, Caudle AS, Hunt KK, Tereffe W, Shaitelman SF, Babiera GV. Timing of Infectious Complications Following Breast-Conserving Therapy with Catheter-Based Accelerated Partial Breast Irradiation. Ann Surg Oncol 21(8):2512-2516, 2014. e-Pub 2014. PMID: 24736987.
Mittendorf EA, Caudle AS, Yang W, Krishnamurthy S, Shaitelman S, Chavez-MacGregor M, Woodward WA, Bedrosian I, Kuerer HM, Hunt KK. Implementation of the American College of Surgeons Oncology Group Z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?. Ann Surg Oncol 21(8):2468-73, 2014. e-Pub 2014. PMID: 24841348.
Rueth NM, Lin HY, Bedrosian I, Shaitelman SF, Ueno NT, Shen Y, Babiera G. Underuse of Trimodality Treatment Affects Survival for Patients With Inflammatory Breast Cancer: An Analysis of Treatment and Survival Trends From the National Cancer Database. J Clin Oncol 32(19):2018-2024, 2014. e-Pub 2014. PMID: 24888808.
MacDermed DM, Houtman KM, Thang SH, Allen PK, Caudle AS, Gainer SM, Hunt KK, Perkins GH, Shaitelman SF, Smith BD, Strom EA, Tereffe W, Woodward WA, Buchholz TA, Hoffman KE. Therapeutic radiation dose delivered to the low axilla during whole breast radiotherapy in the prone position: implications for targeting the undissected axilla. Pract Radiat Oncol 4(2):116-122, 2014. e-Pub 2014. PMID: 24890352.
Shaitelman SF, Khan AJ, Woodward WA, Arthur DW, Cuttino LW, Bloom ES, Shah C, Freedman GM, Wilkinson JB, Babiera GV, Julian TB, Vicini FA. Shortened radiation therapy schedules for early stage breast cancer: A review of hypofractionated whole breast irradiation and accelerated partial breast irradiation. Breast J 20(2):131-46, 2014. e-Pub 2014. PMID: 24479632.
Wang X, Zhang X, Li X, Amos RA, Shaitelman SF, Hoffman K, Howell R, Salehpour M, Zhang SX, Sun TL, Smith B, Tereffe W, Perkins GH, Buchholz TA, Strom EA, Woodward WA. Accelerated partial-breast irradiation using intensity-modulated proton radiotherapy: do uncertainties outweigh potential benefits?. Br J Radiol 86(1029):20130176, 2013. e-Pub 2013. PMID: 23728947.
Vicini FA, Shaitelman S, Wilkinson JB, Shah C, Ye H, Kestin LL, Goldstein NS, Chen PY, Martinez AA. Long-term impact of young age at diagnosis on treatment outcome and patterns of failure in patients with ductal carcinoma in situ treated with breast-conserving therapy. Breast J 19(4):365-73, 2013. e-Pub 2013. PMID: 23815268.
Wilkinson JB, Beitsch PD, Shah C, Arthur D, Haffty BG, Wazer DE, Keisch M, Shaitelman SF, Lyden M, Chen PY, Vicini FA. Evaluation of Current Consensus Statement Recommendations for Accelerated Partial Breast Irradiation: A Pooled Analysis of William Beaumont Hospital and American Society of Breast Surgeon MammoSite(®) Registry Trial Data. Int J Radiat Oncol Biol Phys 85(5):1179-85, 2013. e-Pub 2013. PMID: 23182700.
Wilkinson JB, Vicini FA, Shah C, Shaitelman S, Jawad MS, Ye H, Kestin LL, Goldstein NS, Martinez AA, Benitez P, Chen PY. Twenty-Year Outcomes after Breast-Conserving Surgery and Definitive Radiotherapy for Mammographically Detected Ductal Carcinoma In Situ. Ann Surg Oncol 19(12):3785-91, 2012. e-Pub 2012. PMID: 22644510.
Shaitelman SF, Wilkinson JB, Kestin LL, Ye H, Goldstein NS, Martinez AA, Vicini FA. Long-Term Outcome in Patients with Ductal Carcinoma in situ Treated with Breast-Conserving Therapy: Implications for Optimal Follow-up Strategies. Int J Radiat Oncol Biol Phys 83(3):e305-12, 2012. e-Pub 2012. PMID: 22417804.
Shah C, Wilkinson JB, Shaitelman S, Grills IS, Chen PY, Dekhne N, Jaiyesimi I, Wallace M, Mitchell CK, Vicini FA. Impact of Lymph Node Status on Clinical Outcomes After Accelerated Partial Breast Irradiation. Int J Radiat Oncol Biol Phys 82(3):e409-14, 2012. e-Pub 2012. PMID: 21944464.
Shaitelman SF, Vicini FA, Grills IS, Martinez AA, Yan D, Kim LH. Differences in Effective Target Volume Between Various Techniques of Accelerated Partial Breast Irradiation. Int J Radiat Oncol Biol Phys 82(1):30-6, 2012. e-Pub 2012. PMID: 21050674.
Shaitelman SF, Grills IS, Kestin LL, Ye H, Nandalur S, Huang J, Vicini FA. Rates of Second Malignancies After Definitive Local Treatment for Ductal Carcinoma In Situ of the Breast. Int J Radiat Oncol Biol Phys 81(5):1244-51, 2011. e-Pub 2011. PMID: 21030159.
Shah C, Wilkinson JB, Shaitelman S, Grills I, Wallace M, Mitchell C, Vicini F. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma. Int J Radiat Oncol Biol Phys 81(4):e547-541, 2011. e-Pub 2011. PMID: 21640491.
Wilkinson JB, Reid RE, Shaitelman SF, Chen PY, Mitchell CK, Wallace MF, Marvin KS, Grills IS, Margolis JM, Vicini FA. Outcomes of Breast Cancer Patients With Triple Negative Receptor Status Treated With Accelerated Partial Breast Irradiation. Int J Radiat Oncol Biol Phys 81(3):S227-S228, 2011. e-Pub 2011. PMID: 21345613.
Shaitelman SF, Kim LH, Grills IS, Chen PY, Ye H, Kestin LL, Yan D, Vicini FA. Predictors of Long-Term Toxicity Using Three-Dimensional Conformal External Beam Radiotherapy To Deliver Accelerated Partial Breast Irradiation. Int J Radiat Oncol Biol Phys 81(3):788, 2011. e-Pub 2011. PMID: 20933342.
Shaitelman SF, Kim LH, Yan D, Martinez AA, Vicini FA, Grills IS. Continuous arc rotation of the couch therapy for the delivery of accelerated partial breast irradiation: a treatment planning analysis. Int J Radiat Oncol Biol Phys 80(3):771-8, 2011. e-Pub 2011. PMID: 20584586.
Beitsch P, Vicini F, Keisch M, Haffty B, Shaitelman S, Lyden M. Five-year outcome of patients classified in the "unsuitable" category using the American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus Panel guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite® Registry trial. Ann Surg Oncol 17 Suppl 3:219-25, 2010. e-Pub 2010. PMID: 20853036.
Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer 116(20):4677-85, 2010. e-Pub 2010. PMID: 20602483.

Invited Articles

Moreno AC, vShaitelman SF, Buchholz TA. A clinical perspective on regional nodal irradiation for breast cancer. Breast 34(Suppl1):S85-S90, 2017. e-Pub 2017. PMID: 28690104.
Shaitelman SF, Cromwell KD, Rasmussen JC, Stout NL, Armer JM, Lasinski BB, Cormier JN. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin 65(1):55-81, 2015. e-Pub 2015. PMID: 25410402.
Shaitelman SF, Kim LH. Accelerated partial-breast irradiation: The current state of our knowledge. Oncology (Williston Park) 27(4):329-42, 2013. e-Pub 2013. PMID: 23781698.
Beitsch PD, Shaitelman SF, Vicini FA. Accelerated partial breast irradiation. J Surg Oncol 103(4):362-8, 2011. e-Pub 2011. PMID: 21337572.
Théberge V, Whelan T, Shaitelman SF, Vicini FA. Altered fractionation: rationale and justification for whole and partial breast hypofractionated radiotherapy. Semin Radiat Oncol 21(1):55-65, 2011. e-Pub 2011. PMID: 21134655.
Shaitelman SF, Vicini FA. Status of accelerated partial breast irradiation. Curr Breast Cancer Rep 2:59-66, 2010. e-Pub 2010.

Manuals, Teaching Aids, Other Teaching Publications

Shaitelman SF. Patient Education, Lymphedema Screening for Breast Cancer Patients. Patient Education Office, The University of Texas MD Anderson Cancer Center, 2015.

Editorials

Shaitelman, SF. ABLATIVE Radiation Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics 121(3):623-625, 2025. PMID: 39909611.
Shaitelman SF. Lymphedema: Time for an Update. Int J Radiat Oncol Biol Phys 102(1):79-81, 2018. PMID: 30102207.
Stecklein SR, Shaitelman SF. Commentary on: DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node- Positive Breast Cancer. Breast Diseases: A Year Book Quarterly 27(3):211-213, 2016.
Shaitelman SF. Commentary On: Global abnormalities in lymphatic function following systemic therapy in patients with breast cancer: Bains SK, Peters AM, Zammit C, et al (St George's, Univ of London, UK; Brighton and Sussex Univ Hosps NHS Trust, UK) Br J Surg 102:534-540,2015. Breast Diseases: a YB Quarterly 26(3):204-205, 2015.
Shaitelman SF. Commentary: Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation: Rodriguez N, Sanz X, Dengra J, et al (Hospital de la Esperanza, Barcelona, Spain) Int J Radiat Oncol Biol Phys 87:1051-1057, 2013. Breast Diseases: A Year Book Quarterly 25(2):160-161, 2014.
Shaitelman SF. Commentary: Randomized Trial of Pentoxifylline and Vitamin E vs Standard Follow-up After Breast Irradiation to Prevent Breast Fibrosis, Evaluated by Tissue Compliance Meter: Jacobson G, Bhatia S, Smith BJ, et al (University of Iowa Hospitals and Clinics, Iowa City) Int J Radiat Oncol Biol Phys 85:604-608, 2013. Breast Diseases Quarterly 24(3):278-279, 2013.
Shaitelman SF, Wagner JM. Commentary on: Time-course of arm lymphedema and potential risk factors for progression of lymphedema after breast conservation treatment for early stage breast cancer: Bar Ad V, Dutta PR, Solin LJ, et al (Univ of Pennsylvania, Philadelphia) Breast J 18:219-225, 2012. Breast Diseases: A Year Book Quarterly 24(1):92-93, 2013.
Shaitelman SF. Commentary on: Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation: Shah C, Wilkinson JB, Baschnagel A, et al (William Beaumont Hosp, Royal Oak, MI; et al) Int J Radiat Oncol Biol Phys 83:1095-1100, 2012. Breast Diseases: A Year Book Quarterly 23(4):371-372, 2013.
Shaitelman SF. Commentary on: Nomograms for predicting the risk of arm lymphedema after axillary dissection in breast cancer: Bevilacqua JLB, Kattan MW, Changhong Y et al (Escola Nacional de Saude Publica/FIOCRUZ, Rio de Janeiro, Brazil; Cleveland Clinic, OH; et al) Ann Surg Oncol 19:2580-2589, 2012. Breast Diseases: A Year Book Quarterly 24(2):159-160, 2013.
Shaitelman SF. Commentary On: Increased rates of long-term complications after MammoSite brachytherapy compared with whole breast radiation therapy: Rosenkranz KM, Tsui E, McCabe EB, et al (Dartmouth Hitchcock Med Ctr, Lebanon, NH; Geisel Med School at Dartmouth, Hanover, NH; et al) J Am Coll Surg 217:497-502, 2013. Breast Diseases: A Year Book Quarterly 25(1):78-80, 2013.
Shaitelman SF. Commentary On: Phase 2 study of pre-excision single-dose intraoperative radiation therapy for early-stage breast cancers: six-year update with application of the ASTRO accelerated partial breast irradiation consensus statement criteria: VanderWalde NA, Jones EL, Kimple RJ, et al (Univ of North Carolina at Chapel Hill; Univ of Wisconsin School of Medicine, Madison) Cancer 119:1736-1743, 2013. Breast Diseases: A Year Book Quarterly 24(4):388-389, 2013.
Shaitelman SF. Commentary on: Outcomes after accelerated partial breast irradiation in patients with ASTRO consensus statement cautionary features: McHaffie DR, Patel RR, Adkison JB, et al (Univ of Wisconsin School of Medicine and Public Health, Madison; Western Radiation Oncology, Mountain View, CA) Int J Radiat Oncol Biol Phys 81:46-51, 2011. Breast Diseases: A Year Book Quarterly 23(1):86-87, 2012.
Shaitelman SF. Sounding a warning bell? Documentation of the increased utilization of accelerated partial breast irradiation. J Natl Cancer Inst 104(1):5-7, 2012. PMID: 22180644.

Book Chapters

Stecklein SR. Locally Advanced Breast Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer, 2019.
Colbert L. Early Stage (I-II) Breast Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer, 2019.
Fang P. Ductal and Lobular Carcinoma in Situ. In: Radiation Oncology A Question-Based Review. Wolters Kluwer, 2019.
Stecklein SR. General Breast Cancer. In: Radiation Oncology A Question-Based Review. Wolters Kluwer, 2019.
DeSnyder SM, Shaitelman SF, Schaverien MV. Lymphedema and Body Image Disturbance. In: Body Image Care for Cancer Patients, Principles and Practice. Oxford, 2018.
Shaitelman SF, Shah C, Kim LH, Vicini FA, Arthur DW, Khan AJ. Breast Brachytherapy. In: Brachytherapy: Applications and Techniques. 2nd. Wolters Kluwer Health, 165-185, 2016.
Shaitelman SF. Careers in Medical Education. In: Physicians' Pathways to Non-Traditional Cancers and Leadership Opportunities. Springer, 2011.
DeSnyder SM, Shaitelman SF. Rehabilitation and management of lymphedema in patients with breast cancer. In: Breast Cancer, 3rd Ed.

Letters to the Editor

Shaitelman, SF, Cabrera, AR, May, KS, Lyons, J. In Reply to Fastner et al. Practical radiation oncology 15: 50-53, 2025.
Shaitelman, SF, Cabrera, AR, May, KS, Lyons, J. In Reply to Kaidar-Person et al. Practical radiation oncology 14: e532-e533, 2024.
Kim L, Shaitelman S. What is the target volume for preoperative accelerated partial breast irradiation (APBI)? In regards to Nichols et al. (Int J Radiat Oncol Biol Phys 2010;77:197-202) and Palta et al. (Int J Radiat Oncol Biol Phys 2010, in Press). Int J Radiat Oncol Biol Phys 80: 314-5; author reply 315-6, 2011.

Less

Selected Presentations & Talks

Local Presentations

2025. Top 5 Clinical Challenges in Breast Radiation Oncology. Invited. IGCT T32 Seminar Course. Houston, Texas, US.
2023. Personal History. Invited. Women's History Month Panel. Houston, TX, US.
2023. Elevated plasma cytokines/chemokines predict and provide evidence of a persistent inflammatory basis for breast cancer-related lymphedema. Conference. Gulf Coast Consortium Immunology Symposium. Houston, TX, US.
2020. Lymph Node Positive Breast Cancer. Conference. Rad Onc 2020. Houston, TX, US.
2019. Radiation Oncology 101 for Clinical Research Staff. Invited. Breast Medical Oncology Research Staff Educational Lectureship Series. Houston, TX, US.
2018. Understanding BRCA: Are Ashkenazi Jews Uniquely Susceptible to Breast Cancer and What Can We Do About It?. Invited. Sciences in the Synagogue Symposium: The End of Illness?. Houston, TX, US.
2018. Screening, Rehabilitation & Management of Lymphedema. Invited. MD Anderson Network Education Symposium. Houston, TX, US.
2018. Adjuvant Radiation for Patients Who are Node Positive at Diagnosis. Invited. Breast Cancer Clinical Translational Research Symposium. Houston, TX, US.
2018. Lymph Node Positive Breast Cancer. Invited. Rad Onc 2018. Houston, TX, US.
2018. Regional Nodal Radiation: What the Radiologist Needs to Know. Invited. 2018 Cancer Imaging and Intervention Conference. Houston, TX, US.
2017. Inter-Section Communication. Invited. Radiation Oncology Morbidity & Mortality Conference. Houston, TX, US.
2017. Referrals to Physical Therapy Following Axillary Lymph Node Dissection. Invited. Breast Surgical Oncology Morbidity and Mortality Conference. Houston, TX, US.
2017. Personal History. Conference. Career Conversations for Summer Experience. Houston, TX, US.
2017. Inflammatory Breast Cancer. Invited. myCancerConnection PIKNIC Survivorship Series. Houston, TX, US.
2017. Psychosocial Issues. Panelist. 2017 Cancer Survivorship Research Symposium. Houston, TX, US.
2016. Updates in Breast Radiation Oncology. Invited. Medical Physics Seminar Series. Houston, TX, US.
2016. Optimizing survivorship for breast cancer patients: creating standardized metrics for the diagnosis of breast cancer-related lymphedema. Conference. 2016 State of the Science Cancer Survivorship Research Symposium. Houston, TX, US.
2016. Defining breast cancer patients at risk of lymphedema: the first step toward determining the impact of lymphedema screening and treatment interventions. Conference. MD Anderson Energy Balance and Cancer Research Retreat. Houston, TX, US.
2015. Breast center lymphedema screening expansion. Poster. Celebrating Improvement at MD Anderson. Houston, TX, US.
2015. Breast center lymphedema screening expansion. Invited. MD Anderson Clinical Safety and Effectiveness Graduation, Session #23. Houston, TX, US.
2015. PMRT: Indications, Targets & Techniques. Invited. Plastic Surgery Grand Rounds. Houston, TX, US.
2014. Accelerated hypofractionated breast radiation therapy: Safety and efficacy issues. Invited. Emerging Strategies in the Personalized Treatment of Breast Cancer. Houston, TX, US.
2014. Accelerated partial breast irradiation. Invited. Clinical Management Conference / Surgical Breast Education Conference. Houston, TX, US.
2014. Management of Breast Cancer. Invited. Rad Onc 2014. Houston, TX, US.
2013. Radiation techniques for early stage breast cancer. Invited. Physician Relations Conference. Houston, TX, US.
2013. Breast: MRI-based clinical protocols. Invited. The Integration of MRI with Radiation Oncology. Houston, TX, US.
2013. Acute radiation toxicities with breast radiation. Invited. Radiation Oncology Quality Assurance Meeting. Houston, TX, US.
2013. Technological advances in radiation oncology to improve survivorship outcomes. Invited. Survivorship Grand Rounds. Houston, TX, US.
2012. Accelerated Partial Breast Irradiation. Invited. Houston, TX, US.

Regional Presentations

2023. Plasma cytokine/chemokines as predictive biomarkers for lymphedema in breast cancer patients. Conference. American Venous Forum. San Antonio, TX, US.
2016. Breast Center Lymphedema Expansion. Conference. The University of Texas System Conference. San Antonio, TX, US.
2016. Perometer variance reduction (for Lymphedema screening). Conference. The University of Texas System Conference. San Antonio, TX, US.
2005. Mental health services at colleges and universities: A brief history. Conference. Harvard Graduate School of Education Student Research Conference. Cambridge, MA, US.

National Presentations

2024. LumiSystem-guided lumpectomy enables informed customization of radiation therapy in select patients with breast cancer. Poster. San Antonio Breast Cancer Symposium. San Antonio, Texas, US.
2024. Eliminating breast surgery for invasive, hormone-positive breast cancers with an exceptional response to endocrine therapy and ablative radiotherapy: a single-arm, phase 2 trial. Conference. San Antonio Breast Cancer Symposium. San Antonio, Texas, US.
2023. Partial Breast Radiation Therapy: What to Tell Patients Now That the Evidence is In. Invited. 40th Annual Miami Breast Cancer Conference. Miami, FL, US.
2022. Fractionation and Toxicity. Invited. American Society for Radiation Oncology Annual Meeting. San Antonio, TX, US.
2022. Looking through skin with near-infrared fluorescence to assess lymphatic health. Conference. 24th Annual State of Georgia Lymphedema Conference. Atlanta, GA, US.
2022. Poster Walk - Meet the Professor. Visiting. American Radium Society Annual Meeting, US.
2022. Lymphedema and Other Quality of Life Considerations. Invited. 39th Annual Miami Breast Cancer Conference. Miami, FL, US.
2022. Dermal backflow, detected by near-infrared fluorescence lymphatic imaging, is an early prognostic marker of breast cancer-related lymphedema. Conference. American Vein & Lymphatic Society Annual Meeting. Championsgate, FL, US.
2022. Radiation Therapy Update - Updates from San Antonio and ESMO. Invited. Advances in Breast Cancer. Virtual, US.
2022. Partial Breast Irradiation Updates. Conference. USC Office of Continuing Medical Education. Los Angeles, CA, US.
2021. Selection of Breast Cancer Patients for Regional Nodal Radiation. Conference. Selection of Breast Cancer Patients for Regional Nodal Radiation. Virtual, US.
2021. Preoperative PBI: MD Anderson Experience. Conference. Preoperative PBI: MD Anderson Experience. Virtual, US.
2020. Mock Breast Tumor Board. Conference. Mock Breast Tumor Board. Houston, TX, US.
2020. Updates in Radiation for Breast Cancer - Updates on APBI for ASTRO Cautionary/Unsuitable Patients. Conference. Updates in Radiation for Breast Cancer - Updates on APBI for ASTRO Cautionary/Unsuitable Patients. Big Sky, MT, US.
2020. Comparing Quality of Life Outcomes After Breast Radiation - External Beam Based APBI. Conference. Comparing Quality of Life Outcomes After Breast Radiation - External Beam Based APBI. Big Sky, MT, US.
2019. Guiding Selection of RT Approach After Lumpectomy. Conference. Guiding Selection of RT Approach After Lumpectomy. San Antonio, TX, US.
2019. Anti-Wolbachia Surface Protein IgG as an Early Marker for Cancer-Related Lymphedema. Conference. Anti-Wolbachia Surface Protein IgG as an Early Marker for Cancer-Related Lymphedema. Houston, TX, US.
2019. Oral Presentation. Germline BRCA1/2 Mutation Status Is Not Associated with Differential Radiation Responsiveness in Patients with Locally Advanced Breast Cancer. Conference. Oral Presentation. Germline BRCA1/2 Mutation Status Is Not Associated with Differential Radiation Responsiveness in Patients with Locally Advanced Breast Cancer, US.
2019. ARRO Meet the Professor. Conference. ARRO Meet the Professor. Chicago, IL, US.
2019. Digital Poster Presentation. Lumpectomy plus Endocrine Therapy or Irradiation in Women Age 70 Years or Older with Hormone Receptor Positive Early Breast Cancer: An Analysis of the National Cancer Database. Conference. Digital Poster Presentation. Lumpectomy plus Endocrine Therapy or Irradiation in Women Age 70 Years or Older with Hormone Receptor Positive Early Breast Cancer: An Analysis of the National Cancer Database. Chicago, IL, US.
2019. Oral Presentation. Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: a large, single-institutional experience. Conference. Oral Presentation. Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: a large, single-institutional experience. Chicago, IL, US.
2019. Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: a large, single-institutional experience. Conference. Outcomes after adjuvant radiotherapy in breast cancer patients with and without germline mutations: a large, single-institutional experience. Chicago, IL, US.
2019. Poster Presentation. Association of a genomic index of sensitivity to endocrine therapy with locoregional recurrence of breast cancer. Conference. Poster Presentation. Association of a genomic index of sensitivity to endocrine therapy with locoregional recurrence of breast cancer. Dallas, TX, US.
2019. Invited Participant. Panelist. ASTRO Think Tank on Genetic Testing and Radiation Therapy Decisions, US.
2018. Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC): NRG Oncology/NSABP B-51/RTOG 1304. Conference. Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to whole breast RT post breast-conserving surgery (BCS) reduces invasive breast cancer recurrence-free interval (IBCR-FI) in patients (pts) with pathologically positive axillary (PPAx) nodes who are ypN0 after neoadjuvant chemotherapy (NC): NRG Oncology/NSABP B-51/RTOG 1304. San Antonio, TX, US.
2018. Invited Oral Presentation. Management of the Axilla and Neoadjuvant Systemic Therapy: Lymphedema and Quality of Life Considerations. Conference. Invited Oral Presentation. Management of the Axilla and Neoadjuvant Systemic Therapy: Lymphedema and Quality of Life Considerations. Chicago, IL, US.
2018. Oral Poster Discussant. Conference. Oral Poster Discussant. San Antonio, TX, US.
2018. Are RT Considerations Different in Pre-pectoral Implants vs. Retro-pectoral Implants?. Conference. Are RT Considerations Different in Pre-pectoral Implants vs. Retro-pectoral Implants?. Washington, DC, US.
2017. Lymphatic abnormalities in pre-surgery breast cancer patients as assessed by near-infrared fluorescence lymphatic imaging. Conference. The Lymphedema Symposium at Harvard Medical School/BIDMC. Boston, MA, US.
2017. Advanced planning techniques for breast radiation. Conference. Radiation & Imaging Educational Symposia. Dallas, TX, US.
2017. Time-Driven Activity-Based Costing (TDABC) in Radiation Oncology: A Method for Implementation. Conference. Time-Driven Activity-Based Costing (TDABC) in Radiation Oncology: A Method for Implementation. San Diego, CA, US.
2016. How to Accrue to NRG Oncology/NSABP B-51/RTOG 1304. Invited. NRG. San Antonio, TX, US.
2016. Successfully Accruing to the Trial-Thoughts from a Top Accruing Site. Conference. Successfully Accruing to the Trial-Thoughts from a Top Accruing Site. Dallas, TX, US.
2016. US View: Target definition, selection criteria and margins for APBI. Conference. US View: Target definition, selection criteria and margins for APBI. San Francisco, CA, US.
2016. NSABP B-51/RTOG 1304. A randomized phase III clinical trial evaluating the role of post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with documented positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy. Conference. NSABP B-51/RTOG 1304. A randomized phase III clinical trial evaluating the role of post-mastectomy chest wall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with documented positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy. Chicago, IL, US.
2016. Poster Presentation, Presenting Author. Initiating a lymphedema screening program for breast cancer patients: Determining variability as a first step towards standardization. Conference. ASCO Quality Care Symposium. Phoenix, AZ, US.
2016. NSABP B-51/ RTOG1304 - Successfully Accruing to The Trial: Thoughts From a Top Accruing Site. Conference. NRG Oncology Semiannual Meeting. Atlanta, GA, US.
2015. Poster Presentation, Co-Author. NRG Oncology/NSABP B-51/RTOG 1304: A Phase III Clinical Trial to Determine if Chest Wall and Regional Nodal Radiotherapy Post Mastectomy or the Addition of Regional Nodal Radiotherapy to Breast Radiotherapy Post Breast-Conserving Surgery Will Reduce Invasive Cancer Events in Patients with Positive Axillary Nodes Who Are ypN0 After Neoadjuvant Chemotherapy. Conference. SABCS 2015. San Antonio, TX, US.
2015. Poster Presentation, Co-Author NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal radiotherapy (CWRNRT) post mastectomy (Mx) or the addition of RNRT to breast RT post breast-conserving surgery (BCS) will reduce invasive cancer events in patients (pts) with positive axillary (Ax) nodes who are ypN0 after neoadjuvant chemotherapy (NC). Conference. ASCO Annual Meeting 2015. Chicago, IL, US.
2014. How neoadjuvant chemotherapy impacts radiation treatment. Conference. US Oncology Network. Dallas, TX, US.
2014. DCIS and Radiation. Conference. 7th Annual Breast Cancer Symposium. Peoria, IL, US.
2014. Postmastectomy radiation and reconstruction. Conference. 7th Annual Breast Cancer Symposium. Peoria, IL, US.
2014. Poster Presentation, Senior Author. Toward developing survivorship care plans for breast cancer patients at high risk for radiation-related cardiac effects. Conference. Poster Presentation, Senior Author. Toward developing survivorship care plans for breast cancer patients at high risk for radiation-related cardiac effects. San Francisco, CA, US.
2014. Poster Presentation, Co-Author: What is normal? Cooperative pooled database to establish typical heart and lung doses for modern radiation therapy. Conference. Poster Presentation, Co-Author: What is normal? Cooperative pooled database to establish typical heart and lung doses for modern radiation therapy. San Francisco, CA, US.
2014. Oral Presentation, Presenting Author. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at 6 months comparred to conventionally fractionated whole breast irradiation: results of a randomized trial. Conference. Oral Presentation, Presenting Author. Hypofractionated whole breast irradiation results in less acute toxicity and improved quality of life at 6 months comparred to conventionally fractionated whole breast irradiation: results of a randomized trial. San Francisco, CA, US.
2014. Digital Poster Discussion Presentation. Presenting Author. The role of ultrasound of the regional nodal basin in staging patients with triple negative breast cancer: implications for local-regional treatment. Conference. Digital Poster Discussion Presentation. Presenting Author. The role of ultrasound of the regional nodal basin in staging patients with triple negative breast cancer: implications for local-regional treatment. San Francisco, CA, US.
2014. Poster Presentation, Presenting Author. Radiation Targets and the Development of Breast Cancer-Related Lymphedema: A Systematic Review of the Literature. Conference. 11th NLN International Conference. Washington, DC, US.
2014. Radiation therapy and breast cancer subtypes. Conference. MD Anderson Cancer Center and MD Anderson Physicians Network Symposium. Boston, MA, US.
2014. Hypofractionated breast irradiation. Conference. MD Anderson Cancer Center and MD Anderson Physicians Network Symposium. Boston, MA, US.
2013. Poster Presentation, Presenting Author. Utilization of accelerated partial-breast irradiation and guideline concordance: Analysis of the National Cancer Database. Conference. Breast Cancer Symposium 2013. San Francisco, CA, US.
2011. Digital Poster Discussion Presentation, Presenting Author. Time to revise the consensus statement guidelines for the use of accelerated partial breast irradiation off protocol?. Conference. Digital Poster Discussion Presentation, Presenting Author. Time to revise the consensus statement guidelines for the use of accelerated partial breast irradiation off protocol?. Miami, FL, US.
2011. Brachytherapy-based accelerated partial breast irradiation. Conference. Brachytherapy-based accelerated partial breast irradiation. Dallas, TX, US.
2010. Poster Presentation, Presenting Author. Equivalent incidence of second malignancies after definitive treatment for ductal carcinoma in situ: a matched pair analysis of surgery and radiation versus surgery alone. Conference. Poster Presentation, Presenting Author. Equivalent incidence of second malignancies after definitive treatment for ductal carcinoma in situ: a matched pair analysis of surgery and radiation versus surgery alone. San Antonio, TX, US.
2010. Poster Presentation, Presenting Author. Continuous arc rotation of the couch: an accelerated partial breast irradiation planning study. Conference. Poster Presentation, Presenting Author. Continuous arc rotation of the couch: an accelerated partial breast irradiation planning study. Orlando, FL, US.
2010. Oral Presentation, Presenting Author. Chronic toxicity profile of hypofractionated, high dose rate brachytherapy boost with pelvic external beam radiation therapy for intermediate- and high-risk prostate cancer. Conference. Oral Presentation, Presenting Author. Chronic toxicity profile of hypofractionated, high dose rate brachytherapy boost with pelvic external beam radiation therapy for intermediate- and high-risk prostate cancer. Atlanta, GA, US.
2009. Poster Presentation, Presenting Author. A comprehensive dose-volume analysis of predictors of pneumonitis and esophagitis following radiotherapy for non-small cell lung cancer. Conference. Poster Presentation, Presenting Author. A comprehensive dose-volume analysis of predictors of pneumonitis and esophagitis following radiotherapy for non-small cell lung cancer. Chicago, IL, US.
2002. Oral Presentation, Presenting Author. Advice from the field: How to design a medical school international health project. Conference. Oral Presentation, Presenting Author. Advice from the field: How to design a medical school international health project. Worcester, MA, US.

International Presentations

2024. Radiation therapy after a complete response in the nodes. Invited. Colombian Congress of Mastology. Cartagena, CO.
2024. Updates to the ASTRO Guidelines on partial breast irradiation. Invited. Colombian Congress of Mastology. Cartagena, CO.
2024. De-escalation of Radiation Therapy for Early Stage Breast Cancer. Invited. Colombian Congress of Mastology. Cartegena, CO.
2023. Real-time, image guided, adaptive radiotherapy: Advances in precision radiation oncology. Conference. Molecular Analysis Precision Oncology (MAP). Paris, FR.
2023. Plenary Discussant: APBI Using Sole Interstitial Multicatheter Brachtherapy - GEC-ESTRO Phase 3 Non-inferiority Trial: Sub-analysis of 10-year Results Reflecting Current ASTRO Recommendations for Patient Selection. Conference. Plenary Discussant: APBI Using Sole Interstitial Multicatheter Brachtherapy - GEC-ESTRO Phase 3 Non-inferiority Trial: Sub-analysis of 10-year Results Reflecting Current ASTRO Recommendations for Patient Selection. Vancouver, CA.
2023. Moderator, Breast Session: Breast Brachytherapy Review and Update. Conference. Moderator, Breast Session: Breast Brachytherapy Review and Update. Vancouver, CA.
2022. Extreme vs. moderate hypofractionation in breast cancer. Conference. Extreme vs. moderate hypofractionation in breast cancer. Cartagena, CO.
2022. Use of genomic platforms in radiotherapy decision-making for ductal carcinoma in situ. Conference. Use of genomic platforms in radiotherapy decision-making for ductal carcinoma in situ. Cartagena, CO.
2022. Axillary radiotherapy for microscopic disease after neoadjuvant therapy. Conference. Axillary radiotherapy for microscopic disease after neoadjuvant therapy. Cartagena, CO.
2022. Precision medicine tools in radiotherapy in breast cancer. Conference. Precision medicine tools in radiotherapy in breast cancer. Cartagena, CO.
2021. Dermal backflow, detected by near-infrared fluorescence lymphatic imaging, is a very accurate early prognostic of breast cancer-related lymphedema development. Conference. Dermal backflow, detected by near-infrared fluorescence lymphatic imaging, is a very accurate early prognostic of breast cancer-related lymphedema development. Copenhagen, DK.
2021. Guiding decisions to omit radiotherapy after breast cancer conservating surgery for DCIS. Can genomic biomarkers help?. Conference. Guiding decisions to omit radiotherapy after breast cancer conservating surgery for DCIS. Can genomic biomarkers help?. Santiago De Cali, CO.
2021. Ultra-hypofractionated radiotherapy. Conference. Ultra-hypofractionated radiotherapy. Santiago De Cali, CO.
2020. Desescalar la terapia locoregional en la terapic sistemica sensible HER2+ EBC (De-escalation of local-regional therapy for HER2 sensitive breast cancer). Conference. Desescalar la terapia locoregional en la terapic sistemica sensible HER2+ EBC (De-escalation of local-regional therapy for HER2 sensitive breast cancer). Virtual, MX.
2019. Consideraciones de Radioterapia en cirugia reconstructiva / Radiation Considerations in Reconstructive Surgery. Conference. Consideraciones de Radioterapia en cirugia reconstructiva / Radiation Considerations in Reconstructive Surgery. Cartagena, CO.
2019. Indicaciones actuales de radioterapia nodal regional / Indications for Regional Nodal Radiation. Conference. Indicaciones actuales de radioterapia nodal regional / Indications for Regional Nodal Radiation. Cartagena, CO.
2019. Indicaciones actuales de Radioterapia en CDIS/ Indications of Radiation for DCIS. Conference. Indicaciones actuales de Radioterapia en CDIS/ Indications of Radiation for DCIS. Cartagena, CO.
2018. Hipofraccionamiento en Mama (Hypofractionation in Breast Cancer). Conference. Hipofraccionamiento en Mama (Hypofractionation in Breast Cancer). Medellin, CO.
2017. Changing Paradigms in Radiation Oncology. Conference. Hemato Oncologos S.A Instituto de Oncologia. Cali, CO.
2017. Indications for regional lymph node radiation. Conference. Hemato Oncologos S.A Instituto de Oncologia. Cali, CO.
2016. Screening, Rehabilitation and Management of Lymphedema. Conference. Screening, Rehabilitation and Management of Lymphedema. Santo Domingo, DO.
2016. Radiation Therapy - tailoring based on stage and biology. Conference. Radiation Therapy - tailoring based on stage and biology. Santo Domingo, DO.
2016. Case Discussion - Adjuvant Systemic Therapy, Rehabilitation, and Survivorship. Conference. Case Discussion - Adjuvant Systemic Therapy, Rehabilitation, and Survivorship. Santo Domingo, DO.
2013. The role of regional nodal irradiation. Conference. V Mastology National Congress. Cartagena, CO.
2013. Cardiac irradiation for breast cancer patients. Conference. V Mastology National Congress. Cartagena, CO.
2013. Accelerated partial breast irradiation. Conference. V Mastology National Congress. Cartagena, CO.
2010. Oral Presentation, Presenting Author. Acceptable long-term toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Conference. Oral Presentation, Presenting Author. Acceptable long-term toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Barcelona, ES.
2005. Medical education: An American perspective. Conference. National University of Singapore. Singapore, SG.
2005. Oral Presentation, Presenting Author. Fourth-year medical students’ practice of evidence-based medicine. Conference. Oral Presentation, Presenting Author. Fourth-year medical students’ practice of evidence-based medicine. Amsterdam, NL.

Formal Peers

2022. Neoadjuvant Radiotherapy - Opportunities for Breast Cancer. Invited. Neoadjuvant Radiotherapy - Opportunities for Breast Cancer. Ann Arbor, MI, US.
2022. Evolving Management of Lymph Node Positive Breast Cancer. Invited. Evolving Management of Lymph Node Positive Breast Cancer. Los Angeles, CA, US.
2020. Why are we so reluctant to treat less than whole breast?. Invited. Why are we so reluctant to treat less than whole breast?. Houston, TX, US.
2019. Radiation Oncology Education for Breast Medical Oncology Research. Invited. Radiation Oncology Education for Breast Medical Oncology Research. Houston, TX, US.
2015. Update on Radiation Treatment in Breast Oncology. Invited. Update on Radiation Treatment in Breast Oncology. McAllen, TX, US.
2014. Updates in nodal treatment from the perspective of the radiation oncologist. Invited. Updates in nodal treatment from the perspective of the radiation oncologist. Boston, MA, US.

Less

Grant & Contract Support

Date:	2023 - 2027
Title:	Autoimmunity in Lymphedema
Funding Source:	Department of Defense (DOD)
Role:	Partnering PI
ID:	PR230366P1

Date:	2023 - 2028
Title:	Image-guided prevention of breast cancer-related lymphedema
Funding Source:	NIH/NCI
Role:	PI
ID:	FP00017976

Date:	2023 - 2028
Title:	Targeting metabolism to combat radioresistance to KEAP1 mutated tumors: mechanisms and pre-clinical translation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00017813

Date:	2023 - 2028
Title:	Topography based treatment planning to improve access to radiotherapy for women across Africa
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1-R01-CA27460

Date:	2023 - 2028
Title:	Lymphatic and systemic immunity changes in post-radiation lymphedema development
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00018166

Date:	2023 - 2028
Title:	Targeting Glutaminase 1 in combination with proton therapy to sensitize KEAP1 mutant tumors: mechanisms and pre-clinical translation
Funding Source:	NIH
Role:	Co-I
ID:	FP00016872

Date:	2023 - 2028
Title:	Prophylactic Compression Sleeve Garments to Prevent Breast Cancer-Related Lymphedema
Funding Source:	NIH
Role:	PI
ID:	FP00016636

Date:	2023 - 2025
Title:	Diffusing alpha-emitters radiation therapy (DaRT) combined with ATR inhibition for antitumor immune activation
Funding Source:	NIH/NCI
Role:	Co-I
ID:	1 R21 CA262965-01A1

Date:	2023 - 2026
Title:	Quantifying Temporal Immunologic Changes with Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
Funding Source:	ARTIDIS
Role:	PI

Date:	2023 - 2027
Title:	Prophylactic Compression Sleeve Garments to Prevent Breast Cancer-Related Lymphedema
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI
ID:	RP230146

Date:	2023 - 2026
Title:	Enhancing proton therapy efficacy by modulating metabolism: mechanisms and pre-clinical translation
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	FP00016748

Date:	2022 - 2026
Title:	P01 Supplemental Funding
Funding Source:	MD Anderson Cancer Center
Role:	Core Lead

Date:	2022 - 2023
Title:	Modulating a Metabolic Pathway to Amplify the Relative Biological Effectiveness of Proton Therapy
Funding Source:	American Association of Physicists in Medicine (AAPM)
Role:	Other Significant Contributor

Date:	2022 - 2023
Title:	Biological optimization of proton therapy through Glutaminase-1 inhibition
Funding Source:	American Association of Physicists in Medicine
Role:	Other Significant Contributor
ID:	FP00016318

Date:	2022 - 2027
Title:	Near Infrared Fluorescence Imaging to Direct and Follow Treatment of Sub-Clinical changes that Precede the Onset of Breast Cancer Related Lymphedema
Funding Source:	NIH/NCI
Role:	Multi-PI
ID:	FP00013991_Res1

Date:	2022 - 2025
Title:	Quantitative Assessment of Temporal Immunologic Changes to Radiotherapy
Funding Source:	Prioritizing Research Innovation & Mentoring Excellence (PRIME), Advisory Council for Clinical Research Leaders (ACCRL)
Role:	PI

Date:	2022 - 2024
Title:	Combining radiation with GLS1 inhibition to sensitize tumors
Funding Source:	MD Anderson Institutional Research Grant
Role:	Co-I

Date:	2022 - 2027
Title:	Statistical Methods for Integration of Multiple Data Sources toward Precision Cancer Medicine
Funding Source:	NIH/NCI
Role:	Co-I
ID:	PA-20-185

Date:	2022 - 2023
Title:	Potentiation of ferroptosis by glutaminase inhibition combined with proton radiotherapy to augment anti-tumor immune response
Funding Source:	Radiation Oncology Strategic Initiative Particle Therapy Seed Grant
Role:	Co-I

Date:	2022 - 2025
Title:	Proton Therapy Combined with Selective PARP inhibition to elicit antitumor immune stimulation
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Principal Investigator-MDACC
ID:	FP00013903

Date:	2022 - 2024
Title:	DaRT in combination with inhibitors of PARP and PD-L1 to enhance immune stimulation
Funding Source:	Alpha Tau Medical
Role:	Co-PI

Date:	2022 - 2022
Title:	Pre-clinical assessment of ART0380 and ART4215 combined with x-rays and protons for radio sensitization and immune stimulation
Funding Source:	Artios Pharma
Role:	Co-PI

Date:	2021 - 2026
Title:	Integrating patient-specific clinical and biological factors towards individualizing utilization of proton and photon radiation therapy: Core 2: Translational Biospecimens and Imaging Biomarkers
Funding Source:	NIH/NCI
Role:	Core Lead
ID:	1P01CA261669-01

Date:	2021 - 2021
Title:	Clonogenic cell survival and double strand break foci measurements in DU145 exposed to protons and treated with boron compounds
Funding Source:	TAE Life Sciences
Role:	Co-I
ID:	FP00009369

Date:	2020 - 2025
Title:	Personalized carbon ion therapy in pancreatic cancer: a model using genomic features of individual tumors
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00010477

Date:	2020 - 2025
Title:	Carbon ion therapy with DNA repair inhibition to enhance anti-tumor immunity
Funding Source:	NIH/NCI
Role:	PI
ID:	FP00010517

Date:	2020 - 2023
Title:	Augmenting Anti-Tumor Immunity Using Radiation in the Setting of DNA Repair Defects
Funding Source:	NIH/NCI
Role:	Co-PI
ID:	R21CA252411

Date:	2020 - 2022
Title:	Radiation to Increase Antitumor Immunity for Tumors with DNA Repair Defects in the Setting of ATR Inhibition
Funding Source:	Emerson Collective
Role:	PI
ID:	FP00009369

Date:	2020 - 2022
Title:	Utilizing Radiation to Increase Antitumor Immunity for Tumors with DNA Repair Defects
Funding Source:	Andrew Sabin Family Foundation Fellowship
Role:	PI

Date:	2020 - 2022
Title:	Enhancing radiation-induced DNA damage to stimulate antitumor immunity in breast cancers with DNA repair defects
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI
ID:	FP00009955

Date:	2020 - 2023
Title:	Co-Development of Standardized MR Protocol Set
Funding Source:	Siemens Healthcare
Role:	Collaborator

Date:	2020 - 2024
Title:	Harnessing DNA repair defects to enhance anti-tumor immunity using radiation
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	FP00005537

Date:	2019 - 2025
Title:	Biomarker Strategic Initiative Pillar for the Division of Radiation Oncology
Funding Source:	J. Donald Childress Foundation
Role:	PI

Date:	2019 - 2020
Title:	Deficiencies in BRCA1 create sensitivity to therapeutic proton beams
Funding Source:	Radiation Oncology Strategic Initiatives Trainee Seed Grant, The University of Texas MD Anderson Cancer Center
Role:	Collaborator

Date:	2019 - 2022
Title:	Enhancing radiation-induced DNA damage to stimulate antitumor immunity in breast cancer: Exploring BRCA1 mutated cancers as an optimal platform
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI
ID:	FP00009955

Date:	2019 - 2021
Title:	A consortium for automated radiotherapy treatment planning in Latin America
Funding Source:	Sister Institution Network Fund, The University of Texas MD Anderson Cancer Center
Role:	Collaborator

Date:	2019 - 2021
Title:	A framework to use DNA Repair to IndiVidualizE Radiotherapy (DRIVER)
Funding Source:	Sister Institution Network Fund, The University of Texas MD Anderson Cancer Center
Role:	Co-I

Date:	2019 - 2021
Title:	Optimizing DNA damage with proton vs. photon radiation to stimulate antitumor immunity in BRCA1 mutated breast cancer
Funding Source:	2019 Andrew Sabin Family Fellows Program, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2019 - 2024
Title:	Omission of Surgery in Excellent Responders to MRI-Guided Stereotactic Ablative Radiotherapy to Breast Cancer
Funding Source:	ROSI Advanced Imaging Initiative Grant, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2019 - 2023
Title:	Eliciting Critical Immune Stimulating Effects in BRCA Mutated Breast Cancer Using Proton Therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	PI
ID:	FP00005537

Date:	2019 - 2020
Title:	Radiation to Stimulate Anti-Cancer Immunity in Breast Cancer
Funding Source:	Institutional Research Grant, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2018 - 2019
Title:	Lymphedema Screening Initiative: A Novel Approach to Early Identification and Treatment of Lymphedema
Funding Source:	Hearst Clinical Innovator Award, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2018 - 2020
Title:	Impacting cancer outcomes through enhanced linear energy transfer proton therapy (ELPT)
Funding Source:	Department of Radiation Oncology Shark Tank, The University of Texas MD Anderson Cancer Center
Role:	Co-I

Date:	2018 - 2019
Title:	Eliciting Critical Immune Stimulating Effects in BRCA Mutated Breast Cancer Using Proton Therapy
Funding Source:	Radiation Oncology Strategic Research Initiatives Seed Grant, The University of Texas MD Anderson Cancer Center
Role:	Co-PI

Date:	2018 - 2021
Title:	Eradication of positive margins during breast cancer surgery using molecular image guidance
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2018 - 2019
Title:	LET-optimized IMPT in intact breast tumors to trigger the innate immune response in triple negative breast cancer
Funding Source:	Radiation Oncology Research Program Seed Grant, The University of Texas MD Anderson Cancer Center
Role:	Co-PI

Date:	2017 - 2019
Title:	Preoperative Radiation to Define Cell Death and Immune Pathways in Breast Cancer
Funding Source:	NIH/NCI
Role:	PI
ID:	FP00001694

Date:	2017 - 2019
Title:	Molecular image-guided surgery for the eradication of positive margins in breast cancer
Funding Source:	Department of Defense (DOD)
Role:	Co-I
ID:	FP00002864

Date:	2017 - 2025
Title:	MD Anderson Cancer Center Start Up Funds
Funding Source:	Start Up Funds, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2017 - 2019
Title:	Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects
Funding Source:	Breast Cancer Moonshot, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2017 - 2019
Title:	Preoperative Breast Radiation: Platform for Understanding Radiation-Induced Cell Death and Immunogenicity
Funding Source:	Institutional Research Grant, The University of Texas MD Anderson Cancer Center
Role:	PI

Date:	2016 - 2018
Title:	Imaging for Early Intervention of Lymphatic Abnormalities After Cancer Treatment
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	R21-PAR-15-340

Date:	2016 - 2021
Title:	Lymphatic and systemic immunity changes in post-radiation lymphedema development
Funding Source:	NIH/NCI
Role:	Co-I
ID:	R01CA201487

Date:	2016 - 2019
Title:	RM1
Funding Source:	Varian
Role:	Collaborator

Date:	2016 - 2022
Title:	Lymphatic and Systemic Immunity Changes in Post-Radiation Lymphedema Development
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5R01CA201487

Date:	2016 - 2020
Title:	Immune changes occurring with the development of post-cancer treatment lymphedema
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2016 - 2019
Title:	Lymphatic and systemic immunity changes in post-radiation lymphedema development
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2016 - 2021
Title:	Reducing the Impact of Breast Cancer-Related Lymphedema: Accurate Characterization as an Essential First Step
Funding Source:	The University of Texas MD Anderson Cancer Center, The Center for Radiation Oncology - Health Services Research
Role:	PI

Date:	2016 - 2019
Title:	Early Surveillance of Onset of Breast Cancer-Related Lymphedema
Funding Source:	American Cancer Society (ACS)
Role:	Co-I

Date:	2015 - 2016
Title:	Screening for breast cancer-related lymphedema: are Texans receiving optimal care?
Funding Source:	Cancer Survivorship Research Seed Money Grant
Role:	PI

Date:	2015 - 2020
Title:	Lymphatic and systemic immunity changes in post-radiation lymphedema development
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2015 - 2017
Title:	Optimizing Lymphedema Screening and Education for Breast Cancer Survivors
Funding Source:	NIH/NCI
Role:	PI

Date:	2015 - 2017
Title:	Battlers of Lymphedema
Funding Source:	Genesis Generation Challenge
Role:	Team Lead

Date:	2015 - 2019
Title:	Early identification and treatment of lymphedema in women with breast cancer: Evaluation of early use of compression to prevent progression and its impact on quality of life
Funding Source:	NIH/NCI
Role:	Co-I
ID:	Research Project Grant (Parent R01)

Date:	2015 - 2019
Title:	Lymphatic and systemic immunity changes in post-radiation lymphedema development
Funding Source:	NIH/NCI
Role:	PI

Date:	2015 - 2017
Title:	Optimizing lymphedema screening and education for breast cancer survivors
Funding Source:	Duncan Family Institute for Cancer Prevention and Risk Assessment
Role:	PI

Date:	2014 - 2019
Title:	Early exercise or compression for high risk breast cancer-related lymphedema
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2014 - 2017
Title:	Lymphatic imaging and systemic immunity in post-radiation treatment lymphedema
Funding Source:	NIH/NCI
Role:	Co-I
ID:	Research Project Grant (Parent R01)

Date:	2014 - 2017
Title:	Lymphatic imaging and systemic immunity in post-radiation treatment lymphedema
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I

Date:	2014 - 2017
Title:	Lymphedema screening and early treatment for breast cancer survivors
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-PI

Date:	2014 - 2017
Title:	Impact of quantified breast and truncal lymphedema on lymphedema symptoms, QOL, body image, and sexual function among women with invasive breast cancer treated with breast conserving surgery and radiation therapy
Funding Source:	American Society of Clinical Oncology (ASCO)
Role:	PI

Date:	2014 - 2017
Title:	Prognostics for breast cancer-related lymphedema through NIRF lymphatic imaging
Funding Source:	American Cancer Society (ACS)
Role:	Co-I
ID:	Research Scholar Grant

Date:	2014 - 2015
Title:	Inflammatory etiology of breast cancer-related lymphedema
Funding Source:	R. Lee Clark Fellow - Clinical Innovator Award
Role:	PI

Date:	2014 - 2019
Title:	Impact of quantified breast and truncal lymphedema on quality of life
Funding Source:	American Cancer Society (ACS)
Role:	PI
ID:	Mentored Research Scholar Grant

Date:	2013 - 2015
Title:	Lymphatic imaging and systemic immunity in post-radiation treatment lymphedema
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2013 - 2016
Title:	Modernizing treatment techniques: Bringing MRI into radiation treatment planning
Funding Source:	MR-Linac Master Research Agreement (Elekta)
Role:	PI

Date:	2013 - 2015
Title:	A novel approach to preventing lymphedema after surgery and radiation for breast cancer
Funding Source:	Duncan Family Institute for Cancer Prevention and Risk Assessment
Role:	PI
ID:	Seed Funding Research Program

Date:	2013 - 2015
Title:	Quantification of lymphatic changes and impact on quality of life for breast cancer survivors
Funding Source:	Duncan Family Institute for Cancer Prevention and Risk Assessment
Role:	PI
ID:	Cancer Survivorship Research Seed Money Grant

Date:	2013 - 2016
Title:	A randomized phase III clinical trial evaluating post-mastectomy chestwall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy
Funding Source:	NIH/NCI
Role:	National Radiation Oncology Co-Chair and MDACC Principal Investigator
ID:	NSABP B51/RTOG1304

CV information above last modified March 14, 2025

Simona F Shaitelman, M.D., Ed.M.

About Dr. Shaitelman

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Sawakuchi and Shaitelman Laboratory

Radiation Oncology Strategic Biomarker Initiative Laboratory

Radiation Oncology Department

Radiation Oncology Division

Help #EndCancer

Simona F Shaitelman, M.D., Ed.M.

About Dr. Shaitelman

Present Title & Affiliation

Primary Appointment

Dual/Joint/Adjunct Appointment

Education & Training

Degree-Granting Education

Postgraduate Training

Board Certifications

Experience & Service

Academic Appointments

Administrative Appointments/Responsibilities

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Manuals, Teaching Aids, Other Teaching Publications

Other Articles

Editorials

Book Chapters

Letters to the Editor

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Sawakuchi and Shaitelman Laboratory

Radiation Oncology Strategic Biomarker Initiative Laboratory

Radiation Oncology Department

Radiation Oncology Division

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer